US20030105090A1 - Pyrazole compounds useful as protein kinase inhibitors - Google Patents

Pyrazole compounds useful as protein kinase inhibitors Download PDF

Info

Publication number
US20030105090A1
US20030105090A1 US10/026,966 US2696601A US2003105090A1 US 20030105090 A1 US20030105090 A1 US 20030105090A1 US 2696601 A US2696601 A US 2696601A US 2003105090 A1 US2003105090 A1 US 2003105090A1
Authority
US
United States
Prior art keywords
ring
membered
hydrogen
aliphatic
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/026,966
Other languages
English (en)
Inventor
David Bebbington
Jean-Damien Charrier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/026,966 priority Critical patent/US20030105090A1/en
Publication of US20030105090A1 publication Critical patent/US20030105090A1/en
Assigned to VERTEX PHARMACEUTICALS INCORPORATED reassignment VERTEX PHARMACEUTICALS INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BEBBINGTON, DAVID, CHARRIER, JEAN-DAMIEN
Priority to US10/736,426 priority patent/US7087603B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention is in the field of medicinal chemistry and relates to compounds that are protein kinase inhibitors, compositions containing such compounds and methods of use. More particularly, this invention relates to compounds that are inhibitors of Aurora-2 protein kinase. The invention also relates to methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.
  • Protein kinases mediate intracellular signal transduction. They do this by effecting a phosphoryl transfer from a nucleoside triphosphate to a protein acceptor that is involved in a signaling pathway.
  • kinases and pathways through which extracellular and other stimuli cause a variety of cellular responses to occur inside the cell. Examples of such stimuli include environmental and chemical stress signals (e.g. osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin, H 2 O 2 ), cytokines (e.g. interleukin-1 (IL-1) and tumor necrosis factor ⁇ (TNF- ⁇ )), and growth factors (e.g.
  • environmental and chemical stress signals e.g. osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin, H 2 O 2
  • cytokines e.g. interleukin-1 (IL-1) and tumor necrosis factor ⁇ (TNF- ⁇ )
  • growth factors e.g.
  • GM-CSF granulocyte macrophage-colony-stimulating factor
  • FGF fibroblast growth factor
  • Aurora-2 is a serine/threonine protein kinase that has been implicated in human cancer, such as colon, breast and other solid tumors. This kinase is believed to be involved in protein phosphorylation events that regulate the cell cycle. Specifically, Aurora-2 may play a role in controlling the accurate segregation of chromosomes during mitosis. Misregulation of the cell cycle can lead to cellular proliferation and other abnormalities. In human colon cancer tissue, the aurora-2 protein has been found to be overexpressed. See Bischoff et al., EMBO J., 1998, 17, 3052-3065; Schumacher et al., J. Cell Biol., 1998, 143, 1635-1646; Kimura et al., J. Biol. Chem., 1997, 272, 13766-13771.
  • Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase comprised of ⁇ and ⁇ isoforms that are each encoded by distinct genes [Coghlan et al., Chemistry & Biology, 7, 793-803 (2000); Kim and Kimmel, Curr. Opinion Genetics Dev., 10, 508-514 (2000)].
  • GSK-3 has been implicated in various diseases including diabetes, Alzheimer's disease, CNS disorders such as manic depressive disorder and neurodegenerative diseases, and cardiomyocete hypertrophy [WO 99/65897; WO 00/38675; and Haq et al., J. Cell Biol. (2000) 151, 117].
  • GSK-3 has been found to phosphorylate and modulate the activity of a number of regulatory proteins. These proteins include glycogen synthase which is the rate limiting enzyme necessary for glycogen synthesis, the microtubule associated protein Tau, the gene transcription factor ⁇ -catenin, the translation initiation factor e1F2B, as well as ATP citrate lyase, axin, heat shock factor-1, c-Jun, c-Myc, c-Myb, CREB, and CEPB ⁇ . These diverse protein targets implicate GSK-3 in many aspects of cellular metabolism, proliferation, differentiation and development.
  • GSK-3 a GSK-3 mediated pathway that is relevant for the treatment of type II diabetes
  • insulin-induced signaling leads to cellular glucose uptake and glycogen synthesis.
  • GSK-3 is a negative regulator of the insulin-induced signal.
  • the presence of insulin causes inhibition of GSK-3 mediated phosphorylation and deactivation of glycogen synthase.
  • the inhibition of GSK-3 leads to increased glycogen synthesis and glucose uptake [Klein et al., PNAS, 93, 8455-9 (1996); Cross et al., Biochem. J., 303, 21-26 (1994); Cohen, Biochem. Soc. Trans., 21, 555-567 (1993); Massillon et al., Biochem J.
  • GSK-3 activity has also been associated with Alzheimer's disease. This disease is characterized by the well-known ⁇ -amyloid peptide and the formation of intracellular neurofibrillary tangles.
  • the neurofibrillary tangles contain hyperphosphorylated Tau protein where Tau is phosphorylated on abnormal sites. GSK-3 has been shown to phosphorylate these abnormal sites in cell and animal models. Furthermore, inhibition of GSK-3 has been shown to prevent hyperphosphorylation of Tau in cells [Lovestone et al., Current Biology 4, 1077-86 (1994); Brownlees et al., Neuroreport 8, 3251-55 (1997)]. Therefore, it is believed that GSK-3 activity may promote generation of the neurofibrillary tangles and the progression of Alzheimer's disease.
  • ⁇ -catenin Another substrate of GSK-3 is ⁇ -catenin which is degradated after phosphorylation by GSK-3.
  • Reduced levels of ⁇ -catenin have been reported in schizophrenic patients and have also been associated with other diseases related to increase in neuronal cell death [Zhong et al., Nature, 395, 698-702 (1998); Takashima et al., PNAS, 90, 7789-93 (1993); Pei et al., J. Neuropathol. Exp, 56, 70-78 (1997)].
  • Z 1 is nitrogen or C-R 8 and Z 2 is nitrogen or CH, wherein at least one of Z 1 and Z 2 is nitrogen;
  • R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T-R 3 , or L-Z-R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • Q is selected from —N(R 4 )—, —O—, —S—, —C(R 6′ ) 2 —, 1,2-cyclopropanediyl, 1,2-cyclobutanediyl, or 1,3-cyclobutanediyl;
  • R 1 is T-(Ring D);
  • Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain, wherein when Q is —C(R 6′ ) 2 —, a methylene unit of said C 1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R 4 )—, —CO—, —CONH—, —NHCO—, —SO 2 —, —SO 2 NH—, —NHSO 2 —, —CO 2 —, —OC(O)—, —OC(O)NH—, or —NHCO 2 —;
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • R 2 and R 2′ are independently selected from —R, —T—W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;
  • R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )N(
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom may be taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
  • each R 6′ is independently selected from hydrogen or a C 1-4 aliphatic group, or two R 6′ on the same carbon atom are taken together to form a 3-6 membered carbocyclic ring;
  • each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring;
  • R 8 is selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 .
  • aliphatic as used herein means straight-chain, branched or cyclic C 1 -C 12 hydrocarbons which are completely saturated or which contain one or more units of unsaturation but which are not aromatic.
  • suitable aliphatic groups include substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
  • alkyl used alone or as part of a larger moiety includes both straight and branched chains containing one to twelve carbon atoms.
  • alkenyl and “alkynyl” used alone or as part of a larger moiety shall include both straight and branched chains containing two to twelve carbon atoms.
  • cycloalkyl used alone or as part of a larger moiety shall include cyclic C 3 -C 12 hydrocarbons which are completely saturated or which contain one or more units of unsaturation, but which are not aromatic.
  • haloalkyl means alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms.
  • halogen means F, Cl, Br, or I.
  • heteroatom means nitrogen, oxygen, or sulfur and includes any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen.
  • nitrogen includes a substitutable nitrogen of a heterocyclic ring.
  • the nitrogen in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl).
  • carrier means an aliphatic ring system having three to fourteen members.
  • carrier refers to rings that are optionally substituted.
  • carrier also include aliphatic rings that are fused to one or more aromatic or nonaromatic rings, such as in a decahydronaphthyl or tetrahydronaphthyl, where the radical or point of attachment is on the aliphatic ring.
  • aryl used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to aromatic ring groups having five to fourteen members, such as phenyl, benzyl, phenethyl, 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl.
  • aryl also refers to rings that are optionally substituted.
  • aryl may be used interchangeably with the term “aryl ring”.
  • Aryl also includes fused polycyclic aromatic ring systems in which an aromatic ring is fused to one or more rings.
  • aryl is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as in an indanyl, phenanthridinyl, or tetrahydronaphthyl, where the radical or point of attachment is on the aromatic ring.
  • heterocycle includes non-aromatic ring systems having five to fourteen members, preferably five to ten, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, or S.
  • heterocyclic rings examples include 3-1H-benzimidazol-2-one, (1-substituted)-2-oxo-benzimidazol-3-yl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl, [1,3]-dioxalanyl, [1,3]-dithiolanyl, [1,3]-dioxanyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholinyl, 3-morpholinyl, 4-morpholinyl, 2-thiomorpholinyl, 3-thiomorpholinyl, 4-thiomorpholinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidiny
  • heterocyclyl or “heterocyclic”, as it is used herein, is a group in which a non-aromatic heteroatom-containing ring is fused to one or more aromatic or non-aromatic rings, such as in an indolinyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the non-aromatic heteroatom-containing ring.
  • heterocycle “heterocyclyl”, or “heterocyclic” whether saturated or partially unsaturated, also refers to rings that are optionally substituted.
  • heteroaryl used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refers to heteroaromatic ring groups having five to fourteen members.
  • heteroaryl rings include 2-furanyl, 3-furanyl, 3-furazanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxadiazolyl, 5-oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrazolyl, 2-pyrazolyl, 3-pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 3-pyr
  • heteroaryl is a group in which a heteroatomic ring is fused to one or more aromatic or nonaromatic rings where the radical or point of attachment is on the heteroaromatic ring. Examples include tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[3,4-d]pyrimidinyl.
  • heteroaryl also refers to rings that are optionally substituted.
  • heteroaryl may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”.
  • An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents.
  • Suitable substituents on the unsaturated carbon atom of an aryl, heteroaryl, aralkyl, or heteroaralkyl group include a halogen, —R o , —OR o , —SRO, 1,2-methylene-dioxy, 1,2-ethylenedioxy, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, —O(Ph), substituted —O(Ph), —CH 2 (Ph), substituted —CH 2 (Ph), —CH 2 CH 2 (Ph), substituted —CH 2 CH 2 (Ph), —NO 2 , —CN, —N(R o ) 2 , —NR o C(O)R o , —NR o C(O)N(RO) 2 , —NR o C 2 R o , —NR o NR o C(O)R o , —NR o NR NR o C(O)
  • substituents on the aliphatic group or the phenyl ring of R o include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
  • An aliphatic group or a non-aromatic heterocyclic ring may contain one or more substituents.
  • suitable substituents on the saturated carbon of an aliphatic group or of a non-aromatic heterocyclic ring include those listed above for the unsaturated carbon of an aryl or heteroaryl group and the following: ⁇ O, ⁇ S, ⁇ NNHR*, ⁇ NN(R*) 2 , ⁇ N—, ⁇ NNHC(O)R*, ⁇ NNHCO 2 (alkyl), ⁇ NNHSO 2 (alkyl), or ⁇ NR*, where each R* is independently selected from hydrogen, an unsubstituted aliphatic group or a substituted aliphatic group.
  • substituents on the aliphatic group include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
  • Suitable substituents on the nitrogen of a non-aromatic heterocyclic ring include —R + , —N(R + ) 2 , —C(O)R + , —CO 2 R + , —C(O)C(O)R + , —C(O)CH 2 C(O)R + , —SO 2 R + , —SO 2 N(R + ) 2 , —C( ⁇ S)N(R + ) 2 , —C( ⁇ NH)—N(R + ) 2 , and —NR + SO 2 R + ; wherein each R + is independently selected from hydrogen, an aliphatic group, a substituted aliphatic group, phenyl (Ph), substituted Ph, —O(Ph), substituted —O(Ph), CH 2 (Ph), substituted CH 2 (Ph), or an unsubstituted heteroaryl or heterocyclic ring.
  • substituents on the aliphatic group or the phenyl ring include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
  • linker group means an organic moiety that connects two parts of a compound.
  • Linkers are typically comprised of an atom such as oxygen or sulfur, a unit such as —NH—, —CH 2 —, —C(O)—, —C(O)NH—, or a chain of atoms, such as an alkylidene chain.
  • the molecular mass of a linker is typically in the range of about 14 to 200, preferably in the range of 14 to 96 with a length of up to about six atoms.
  • linkers include a saturated or unsaturated C 1-6 alkylidene chain which is optionally substituted, and wherein one or two saturated carbons of the chain are optionally replaced by —C(O)—, —C(O)C(O)—, —CONH—, —CONHNH—, —CO 2 —, —OC(O)—, —NHCO 2 —, —O—, —NHCONH—, —OC(O)NH—, —NHNH—, —NHCO—, —S—, —SO—, —SO 2 —, —NH—, —SO 2 NH—, or —NHSO 2 —.
  • alkylidene chain refers to an optionally substituted, straight or branched carbon chain that may be fully saturated or have one or more units of unsaturation.
  • the optional substituents are as described above for an aliphatic group.
  • a combination of substituents or variables is permissible only if such a combination results in a stable or chemically feasible compound.
  • a stable compound or chemically feasible compound is one in which the chemical structure is not substantially altered when kept at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.
  • structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • compositions may be formulated into compositions.
  • the composition is a pharmaceutical composition.
  • the composition comprises an amount of the protein kinase inhibitor effective to inhibit a protein kinase, particularly Aurora-2, in a biological sample or in a patient.
  • Compounds of this invention and pharmaceutical compositions thereof, which comprise an amount of the protein kinase inhibitor effective to treat or prevent an Aurora-2-mediated condition and a pharmaceutically acceptable carrier, adjuvant, or vehicle, may be formulated for administration to a patient.
  • Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof.
  • Aurora-2-mediated disease or “Aurora-2-mediated condition”, as used herein, means any disease or other deleterious condition in which Aurora is known to play a role.
  • the terms “Aurora-2-mediated disease” or “Aurora-2-mediated condition” also mean those diseases or conditions that are alleviated by treatment with an Aurora-2 inhibitor. Such conditions include, without limitation, colon, breast, stomach, and ovarian cancer.
  • Another aspect of the invention relates to inhibiting Aurora-2 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 inhibitor of formula I, or a composition thereof.
  • Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof.
  • GSK-3-mediated disease or “GSK-3-mediated condition”, as used herein, mean any disease or other deleterious condition or state in which GSK-3 is known to play a role.
  • diseases or conditions include, without limitation, diabetes, Alzheimer's disease, Huntington's Disease, Parkinson's Disease, AIDS-associated dementia, amyotrophic lateral sclerosis (AML), multiple sclerosis (MS), schizophrenia, cardiomycete hypertrophy, reperfusion/ischemia, and baldness.
  • One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
  • Another aspect of the invention relates to inhibiting GSK-3 activity in a biological sample, which method comprises contacting the biological sample with a GSK-3 inhibitor of formula I.
  • Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a CDK-2-mediated disease with a CDK-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof.
  • CDK-2-mediated disease or “CDK-2-mediated condition”, as used herein, mean any disease or other deleterious condition in which CDK-2 is known to play a role.
  • CDK-2-mediated disease or “CDK-2-mediated condition” also mean those diseases or conditions that are alleviated by treatment with a CDK-2 inhibitor. Such conditions include, without limitation, cancer, Alzheimer's disease, restenosis, angiogenesis, glomerulonephritis, cytomegalovirus, HIV, herpes, psoriasis, atherosclerosis, alopecia, and autoimmune diseases such as rheumatoid arthritis. See Fischer, P. M. and Lane, D.
  • Another aspect of the invention relates to inhibiting CDK-2 activity in a biological sample or a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing an ERK-2-mediated diseases with an ERK-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof.
  • ERK-mediated disease or “ERK-mediated condition”, as used herein mean any disease or other deleterious condition in which ERK is known to play a role.
  • ERK-2-mediated disease or “ERK-2-mediated condition” also mean those diseases or conditions that are alleviated by treatment with a ERK-2 Inhibitor. Such conditions include, without limitation, cancer, stroke, diabetes, hepatomegaly, cardiovascular disease including cardiomegaly, Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, atherosclerosis, restenosis, psoriasis, allergic disorders including asthma, inflammation, neurological disorders and hormone-related diseases.
  • cancer includes, but is not limited to the following cancers: breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma, bone, colon, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, and
  • ERK-2 protein kinase and its implication in various diseases has been described [Bokemeyer et al. 1996, Kidney Int. 49, 1187; Anderson et al., 1990, Nature 343, 651; Crews et al., 1992, Science 258, 478; Bjorbaek et al., 1995, J. Biol. Chem. 270, 18848; Rouse et al., 1994, Cell 78, 1027; Raingeaud et al., 1996, Mol. Cell Biol. 16, 1247; Raingeaud et al. 1996; Chen et al., 1993 Proc. Natl. Acad. Sci. USA 90, 10952; Oliver et al., 1995, Proc.
  • Another aspect of the invention relates to inhibiting ERK-2 activity in a biological sample or a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing an AKT-mediated diseases with an AKT inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof.
  • AKT-mediated disease or “AKT-mediated condition”, as used herein, mean any disease or other deleterious condition in which AKT is known to play a role.
  • the terms “AKT-mediated diseases” or “AKT-mediated condition” also mean those diseases or conditions that are alleviated by treatment with a AKT inhibitor.
  • AKT-mediated diseases or conditions include, but are not limited to, proliferative disorders, cancer, and neurodegenerative disorders.
  • the association of AKT, also known as protein kinase B, with various diseases has been described [Khwaja, A., Nature, pp. 33-34, 1990; Zang, Q. Y., et al, Oncogene, 19 2000; Kazuhiko, N., et al, The Journal of Neuroscience, 20 2000].
  • Another aspect of the invention relates to inhibiting AKT activity in a biological sample or a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a Src-mediated disease with a Src inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof.
  • Src-mediated disease or “Src-mediated condition”, as used herein mean any disease or other deleterious condition in which Src is known to play a role.
  • the terms “Src-mediated disease” or “Src-mediated condition” also mean those diseases or conditions that are alleviated by treatment with a Src inhibitor. Such conditions include, without limitation, hypercalcemia, osteoporosis, osteoarthritis, cancer, symptomatic treatment of bone metastasis, and Paget's disease.
  • Src protein kinase and its implication in various diseases has been described [Soriano, Cell, 69, 551 (1992); Soriano et al., Cell, 64, 693 (1991); Takayanagi, J. Clin.
  • Another aspect of the invention relates to inhibiting Src activity in a biological sample or a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing an Lck-mediated diseases with an Lck inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof.
  • Lck-mediated disease or “Lck-mediated condition”, as used herein, mean any disease state or other deleterious condition in which Lck is known to play a role.
  • Lck-mediated disease or “Lck-mediated condition” also mean those diseases or conditions that are alleviated by treatment with an Lck inhibitor.
  • Lck-mediated diseases or conditions include, but are not limited to, autoimmune diseases such as transplant rejection, allergies, rheumatoid arthritis, and leukemia. The association of Lck with various diseases has been described [Molina et al., Nature, 357, 161 (1992)].
  • Another aspect of the invention relates to inhibiting Lck activity in a biological sample or a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
  • pharmaceutically acceptable carrier, adjuvant, or vehicle refers to a non-toxic carrier, adjuvant, or vehicle that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof.
  • patient includes human and veterinary subjects.
  • biological sample includes, without limitation, cell cultures or extracts thereof; preparations of an enzyme suitable for in vitro assay; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • An amount effective to inhibit protein kinase for example, Aurora-2 and GSK-3, is an amount that causes measurable inhibition of the kinase activity when compared to the activity of the enzyme in the absence of an inhibitor. Any method may be used to determine inhibition, such as, for example, the Biological Testing Examples described below.
  • Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions are generally known in the art. They include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • ion exchangers alumina, aluminum stearate, lecithin
  • serum proteins such as human serum albumin
  • buffer substances such as phosphates
  • compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally, intraperitoneally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • a long-chain alcohol diluent or dispersant such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • compositions of this invention may be administered in the form of suppositories for rectal administration.
  • suppositories for rectal administration.
  • a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
  • compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
  • the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
  • compositions of this invention may also be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • compositions to treat or prevent the above-identified diseases or disorders.
  • a “pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
  • Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.
  • compositions of this invention include, without limitation, the following derivatives of the present compounds: esters, amino acid esters, phosphate esters, metal salts sulfonate esters, carbamates, and amides.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
  • suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate
  • Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and N+(C 1-4 alkyl) 4 salts.
  • alkali metal e.g., sodium and potassium
  • alkaline earth metal e.g., magnesium
  • ammonium e.g., sodium and potassium
  • N+(C 1-4 alkyl) 4 salts e.g., sodium and potassium
  • alkaline earth metal e.g., magnesium
  • ammonium e.g., sodium and potassium
  • compositions should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of-factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • the amount of the inhibitor will also depend upon the particular compound in the composition.
  • additional therapeutic agents which are normally administered to treat or prevent that condition, may be administered together with the inhibitors of this invention.
  • additional therapeutic agents which are normally administered to treat or prevent that condition, may be administered together with the inhibitors of this invention.
  • chemotherapeutic agents or other anti-proliferative agents may be combined with the present compounds to treat cancer.
  • agents include, without limitation, adriamycin, dexamethasone, vincristine, cyclophosphamide, fluorouracil, topotecan, taxol, interferons, and platinum derivatives.
  • agents for treating diabetes such as insulin or insulin analogues, in injectable or inhalation form, glitazones, alpha glucosidase inhibitors, biguanides, insulin sensitizers, and sulfonyl ureas
  • anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine
  • immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophophamide, azathioprine, and sulfasalazine
  • neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers,
  • those additional agents may be administered separately from the protein kinase inhibitor-containing composition, as part of a multiple dosage regimen.
  • those agents may be part of a single dosage form, mixed together with the protein kinase inhibitor of this invention in a single composition.
  • R x and R y may be taken together to form a fused ring, providing a bicyclic ring system containing Ring A.
  • Preferred R x X/R y rings include a 5-, 6-, or 7-membered unsaturated or partially unsaturated ring having 0-2 heteroatoms, wherein said R x /R y ring is optionally substituted.
  • Examples of bicyclic systems containing Ring A are shown below by compounds I-A through I-BB, wherein Z 1 is nitrogen or C(R 8 ) and Z 2 is nitrogen or C(H).
  • Preferred bicyclic Ring A systems include I-A, I-B, I-C, I-D, I-E, I-F, I-I, I-J, I-K, I-P, I-Q, I-V, and I-U, more preferably I-A, I-B, I-D, I-E, I-J, I-P, and I-V, and most preferably I-A, I-B, I-D, I-E and I-J.
  • R x groups when present, include hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group such as methyl, ethyl, cyclopropyl, or isopropyl.
  • Preferred R y groups when present, include T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene, L is —O—, —S—, —C(R 6 ) 2 O—, —CO—or —N(R 4 )—, and R 3 is —R, —N(R 4 ) 2 , or —OR.
  • R y groups include 5-6 membered heteroaryl or heterocyclyl rings, such as 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl; C 1-6 aliphatic, such as methyl, ethyl, cyclopropyl, isopropyl, or t-butyl; alkoxyalkylamino such as methoxyethylamino;, alkoxyalkyl such as methoxymethyl or methoxyethyl; alkyl- or dialkylamino such as ethylamino or dimethylamino; alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy; acetamido; and optionally substituted phenyl such as phenyl or halo-substituted phenyl.
  • C 1-6 aliphatic such as methyl, ethyl,
  • the ring formed when R x and R y are taken together may be substituted or unsubstituted.
  • Suitable substituents include —R, halo, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —OR, —N(R 4)—(CH 2) 2-4 —N(R 4 ) 2 , —N(R 4 )—(CH 2 ) 2-4 —R, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted
  • R x /R y ring substituents include -halo, —R, —OR, —COR, —CO 2 R, —CON(R 4 ) 2 , —CN, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —NO 2 —N(R 4 ) 2 , —NR 4 COR, —NR 4 SO 2 R, —SO 2 N(R 4 ) 2 wherein R is hydrogen or an optionally substituted C 1-6 aliphatic group.
  • R 2 and R 2′ may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring, wherein said fused ring is optionally substituted.
  • Preferred substituents on the R 2 /R 2′ fused ring include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-3 alkyl, —C 1-3 haloalkyl, —NO 2 , —O(C 1-3 alkyl), —CO 2 (C 1-3 alkyl), —CN, —SO 2 (C 1-3 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-3 alkyl), —NHC(O)(C 1-3 alkyl), —C(O)NH 2 , and —CO(C 1-3 alkyl), wherein the (C 1-3 alkyl) is most preferably methyl.
  • preferred R 2 groups include hydrogen, C 1-4 aliphatic, alkoxycarbonyl, (un)substituted phenyl, hydroxyalkyl, alkoxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, phenylaminocarbonyl, and (N-heterocyclyl)carbonyl.
  • R 2 substituents include methyl, cyclopropyl, ethyl, isopropyl, propyl, t-butyl, cyclopentyl, phenyl, CO 2 H, CO 2 CH 3 , CH 2 OH, CH 2 OCH 3 , CH 2 CH 2 CH 2 OH, CH 2 CH 2 CH 2 OCH 3 , CH 2 CH 2 CH 2 OCH 2 Ph, CH 2 CH 2 CH 2 NH 2 , CH 2 CH 2 CH 2 NHCOOC(CH 3 ) 3 , CONHCH(CH 3 ) 2 , CONHCH 2 CH ⁇ CH 2 , CONHCH 2 CH 2 OCH 3 , CONHCH 2 Ph, CONH(cyclohexyl), CON(Et) 2 , CON(CH 3 )CH 2 Ph, CONH(n-C 3 H 7 ), CON(Et)CH 2 CH 2 CH 3 , CONHCH 2 CH(CH 3 ) 2 , CON(n-C 3 H 7 ) 2 , CO(
  • R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D);
  • Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 —, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • R 2 and R 2′ are independently selected from —R, —T—W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2 is independently substituted by R 4 ;
  • R 3 is selected from —R, -halo, —OR, —C ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON (R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R.
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; and each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring.
  • Preferred rings formed by R x and R y include a 5-, 6-, or 7-membered unsaturated or partially unsaturated ring having 0-2 heteroatoms, wherein said R x /R y ring is optionally substituted.
  • This provides a bicyclic ring system containing a pyrimidine ring. Examples of preferred pyrimidine ring systems of formula IIa are shown below.
  • More preferred pyrimidine ring systems of formula IIa include IIa-A, IIa-B, IIa-D, IIa-E, IIa-J, lIa-P, and IIa-V, most preferably IIa-A, IIa-B, IIa-D, IIa-E, and IIa-J.
  • the ring formed when R x and R y are taken together may be substituted or unsubstituted.
  • Suitable substituents include —R, halo, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —OR, —(R 4 )—(CH 2 ) 2-4 —(R 4 ) 2 , —N(R 4 )—(CH 2 ) 2-4 —R, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic
  • R x /R y ring substituents include -halo, —R, —OR, —COR, —CO 2 R, —CON(R 4 ) 2 , —CN, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —NO 2 —N(R 4 ) 2 , —NR 4 COR, —NR 4 SO 2 R, —SO 2 N(R 4 ) 2 wherein R is hydrogen or an optionally substituted C 1-6 aliphatic group.
  • R 2 and R 2′ groups of formula IIa may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IIa compounds having a pyrazole-containing bicyclic ring system:
  • Preferred substituents on the R 2 /R 2′ fused ring of formula IIa include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CN, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O)(C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
  • the (C 1-4 alkyl) group is methyl or ethyl.
  • preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
  • preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
  • a preferred R 2′ group is hydrogen.
  • Ring D of formula IIa is monocyclic
  • preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Ring D of formula IIa is bicyclic
  • preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
  • T—R 5 or V—Z—R 5 substituents include -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 4 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic
  • R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAC, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(C O 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
  • Preferred formula IIa compounds have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-2 heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
  • Ring D is a 5-7 membered monocyclic ring or an 8-10 membered bicyclic ring selected from an aryl or heteroaryl ring;
  • R 2 is —R or —T—W—R6 and R 2′ is hydrogen; or R 2 and R 2′ are taken together to form an optionally substituted benzo ring; and
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 .
  • More preferred compounds of formula IIa have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x and R y are taken together to form a benzo, pyrido, cyclopento, cyclohexo, cyclohepto, thieno, piperidino, or imidazo ring;
  • R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered monocyclic ring or an 8-10 membered bicyclic ring selected from an aryl or heteroaryl ring;
  • R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —N(R 4 )—.
  • R x and R y are taken together to form a benzo, pyrido, piperidino, or cyclohexo ring;
  • R 1 is T-Ring D, wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring;
  • R 2 is hydrogen or C 1-4 aliphatic and R 2′ is hydrogen;
  • R 3 is selected from —R. —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —NH—; and
  • Ring D is substituted by up to three substituents selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
  • this invention provides a composition comprising a compound of formula IIa and a pharmaceutically acceptable carrier.
  • Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIa or a pharmaceutical composition thereof.
  • Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IIa or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIa or a pharmaceutical composition thereof.
  • One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IIa or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
  • Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IIa or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a CDK-2-mediated disease with a CDK-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIa or a pharmaceutical composition thereof.
  • Another aspect of the invention relates to inhibiting CDK-2 activity in a patient, which method comprises administering to the patient a compound of formula IIa or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a Src-mediated disease with a Src inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIa or a pharmaceutical composition thereof.
  • Another aspect of the invention relates to inhibiting Src activity in a patient, which method comprises administering to the patient a compound of formula IIa or a composition comprising said compound.
  • Another method relates to inhibiting Aurora-2, GSK-3, CDK2, or Src activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2, GSK-3, CDK2, or Src inhibitor of formula IIa, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2, GSK-3, CDK2, or Src.
  • Each of the aforementioned methods directed to the inhibition of Aurora-2, GSK-3, CDK2, or Src, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of formula IIa, as described above.
  • Another embodiment of this invention relates to compounds of formula IIb:
  • R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D);
  • Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 1 or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 ) 13 , —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • R 2 and R 2′ are independently selected from —R, —T—W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;
  • R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )N(
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —NP(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
  • each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring.
  • Preferred rings formed by R x and R y include a 5-, 6-, or 7-membered unsaturated or partially unsaturated ring having 0-2 heteroatoms, wherein said R x /R y ring is optionally substituted.
  • This provides a bicyclic ring system containing a pyrimidine ring. Examples of preferred pyrimidine ring systems of formula IIb are shown below.
  • More preferred pyrimidine ring systems of formula IIb include IIB-A, IIb-B, IIb-D, IIb-E, IIb-J, IIB-P, and IIb-V, most preferably IIB-A, IIb-B, IIb-D, IIb-E, and IIb-J.
  • the ring formed when R x and R y are taken together may be substituted or unsubstituted.
  • Suitable substituents include —R, halo, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —OR, —(R 4 )—(CH 2 ) 2-4 —(R 4 ) 2 , —(R 4 )—(CH 2 ) 2-4 —R, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic),
  • R x /R y ring substituents include -halo, —R, —OR, —COR, —CO 2 R, —CON(R 4 ) 2 , —CN, —O(CH 2 ) 2-4 —(R 4 ) 2 , —O(CH 2 ) 2-4 —R—NO 2 —N(R 4 ) 2 , —NR 4 COR, —NR 4 SO 2 R, —SO 2 N(R 4 ) 2 wherein R is hydrogen or an optionally substituted C 1-6 aliphatic group.
  • R 2 and R 2′ groups of formula IIb may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IIb compounds having a pyrazole-containing bicyclic ring system:
  • Preferred substituents on the R 2 /R 2′ fused ring of formula IIb include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CN, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O)(C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
  • the (C 1-4 alkyl) group is methyl or ethyl.
  • preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
  • preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
  • a preferred R 2 group is hydrogen.
  • Ring D of formula IIb is monocyclic
  • preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Ring D of formula IIb is bicyclic
  • preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
  • preferred T—R 5 or V—Z—R 5 substituents include -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —(R 6 )COCH 2 N(R 4 ) 2 , —(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
  • R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAc, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
  • Preferred formula IIb compounds have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-2 heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 1 or L—Z—R 3 1 and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
  • Ring D is a 5-7 membered monocyclic ring or an 8-10 membered bicyclic ring selected from an aryl or heteroaryl ring;
  • R 2 is —R or —T—W—R 6 and R 2 is hydrogen; or R 2 and R 2 are taken together to form an optionally substituted benzo ring; and
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 .
  • More preferred compounds of formula IIb have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x and R y are taken together to form a benzo, pyrido, cyclopento, cyclohexo, cyclohepto, thieno, piperidino, or imidazo ring;
  • R 6 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered monocyclic ring or an 8-10 membered bicyclic ring selected from an aryl or heteroaryl ring;
  • R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —N(R 4 )—.
  • R x and R y are taken together to form a benzo, pyrido, piperidino, or cyclohexo ring;
  • R 1 is T-Ring D, wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring;
  • R 2 is hydrogen or C 1-4 aliphatic and R 2′ is hydrogen;
  • R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —NH—; and
  • Ring D is substituted by up to three substituents selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
  • this invention provides a composition comprising a compound of formula IIb and a pharmaceutically acceptable carrier.
  • Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIb or a pharmaceutical composition thereof.
  • Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IIb or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIb or a pharmaceutical composition thereof.
  • One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IIb or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
  • Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IIb or a composition comprising said compound.
  • Another method relates to inhibiting Aurora-2 or GSK-3 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 or GSK-3 inhibitor of formula IIb, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2 or GSK-3.
  • R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D);
  • Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO 2 —, —C(R) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 O—,
  • R 2 and R 2 are independently selected from —R, —T—W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2 is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;
  • R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )N(
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )——C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 20 —, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
  • each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring.
  • Preferred rings formed by R x and R y include a 5-, 6-, or 7-membered unsaturated or partially unsaturated ring having 0-2 heteroatoms, wherein said R x /R y ring is optionally substituted.
  • This provides a bicyclic ring system containing a pyrimidine ring. Examples of preferred pyrimidine ring systems of formula IIc are shown below.
  • More preferred pyrimidine ring systems of formula IIc include IIc-A, IIc-B, IIC-D, IIc-E, IIC-J, IIc-P, and IIc-V, most preferably IIc-A, IIc-B, IIc-D, IIc-E, and IIc-J.
  • R x and R y of formula IIc may be substituted or unsubstituted.
  • Suitable substituents include —R, halo, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —OR, —N(R 4 )—(CH 2 ) 2-4 —N(R 4 ) 2 , —N(R 4 )—(CH 2 ) 2-4 —R, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C
  • R x /R y ring substituents include -halo, —R, —OR, —COR, —CO 2 R, —CON(R 4 ) 2 , —CN, —O(CH 2 ) 2 — 4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —NO 2 —N(R 4 ) 2 , —NR 4 COR, —NR 4 SO 2 R, —SO 2 N(R 4 ) 2 wherein R is hydrogen or an optionally substituted C 1-6 aliphatic group.
  • R 2 and R 2 groups of formula IIc may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IIc compounds having a pyrazole-containing bicyclic ring system:
  • Preferred substituents on the R 2 /R 2′ fused ring of formula IIc include one or more of the following: is -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CN, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O)(C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
  • the (C 1-4 alkyl) group is methyl.
  • preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
  • preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
  • a preferred R 2′ group is hydrogen.
  • Ring D of formula IIc is monocyclic
  • preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Ring D of formula IIc is bicyclic
  • preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
  • preferred T—R 5 or V—Z—R 5 substituents include -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R)COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
  • R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAc, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
  • Preferred formula IIc compounds have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-2 heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 1 and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
  • Ring D is a 5-7 membered monocyclic ring or an 8-10 membered bicyclic ring selected from an aryl or heteroaryl ring;
  • R 2 is —R or —T—W—R 6 and R 2′ is hydrogen; or R 2 and R 2′ are taken together to form an optionally substituted benzo ring; and
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 .
  • More preferred compounds of formula IIc have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x and R y are taken together to form a benzo, pyrido, cyclopento, cyclohexo, cyclohepto, thieno, piperidino, or imidazo ring;
  • R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered monocyclic ring or an 8-10 membered bicyclic ring selected from an aryl or heteroaryl ring;
  • R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —N(R 4 )—.
  • R x and R y are taken together to form a benzo, pyrido, piperidino, or cyclohexo ring;
  • R 1 is T-Ring D, wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring;
  • R 2 is hydrogen or C 1-4 aliphatic and R 2 ′ is hydrogen;
  • R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —NH—; and
  • Ring D is substituted by up to three substituents selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
  • Preferred compounds of formula IIc include compounds of formula IIc′:
  • R x and R y are taken together with their intervening atoms to form a fused benzo ring, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by T—R 3 1 or L—Z—R 3 ;
  • R 1 is T— (Ring D);
  • Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO 2 N
  • R 2 and R 2′ are independently selected from —R, —T—W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;
  • R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 ) N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )N(
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
  • each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring.
  • the ring formed when R x and R y of formula IIc′ are taken together may be substituted or unsubstituted.
  • Suitable substituents include —R, halo, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —OR, —N(R 4 )—(CH 2 ) 2-4 —N(R 4 ) 2 , —N(R 4 )—(CH 2 ) 2-4 —R, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted
  • R x /R y ring substituents include -halo, —R, —OR, —COR, —CO 2 R, —CON(R 4 ) 2 , —CN, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, , —NO 2 —N(R 4 ) 2 , —NR 4 COR, —NR 4 SO 2 R, —SO 2 N(R 4 ) 2 , wherein R is hydrogen or an optionally substituted C 1-6 aliphatic group.
  • R 2 and R 2 groups of formula IIc′ may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IIc′ compounds having a pyrazole-containing bicyclic ring system:
  • Preferred substituents on the R 2 /R 2′ ′fused ring of formula IIc′ include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CN, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O)(C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
  • the (C 1-4 alkyl) group is methyl.
  • preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
  • preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
  • a preferred R 2′ group is hydrogen.
  • Ring D of formula IIc′ is monocyclic
  • preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Ring D of formula IIc′ is bicyclic
  • preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
  • T—R 5 or V—Z—R 5 substituents include -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic
  • R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAc, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
  • Preferred formula IIc′ compounds have one or more, and more preferably all, of the features selected from the group consisting of:
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
  • Ring D is a 5-7 membered monocyclic ring or an 8-10 membered bicyclic ring selected from an aryl or heteroaryl ring;
  • R 2 is —R or —T—W—R 6 and R 2 is hydrogen; or R 2 and R 2 are taken together to form an optionally substituted benzo ring; and
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 .
  • More preferred compounds of formula IIc′ have one or more, and more preferably all, of the features selected from the group consisting of:
  • R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered monocyclic ring or an 8-10 membered bicyclic ring selected from an aryl or heteroaryl ring;
  • R 2 is —R and R 2 is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —N(R 4 )—.
  • R 1 is T-Ring D, wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring;
  • R 2 is hydrogen or C 1-4 aliphatic and R 2′ is hydrogen;
  • R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —NH—; and
  • Ring D is substituted by up to three substituents selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
  • R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is optionally substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is optionally substituted by R 4 ; provided that said fused ring formed by R x and R y is other than benzo;
  • R 1 is T-(Ring D);
  • Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • R 2 and R 2′ are independently selected from —R, —T—W—R 6, or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;
  • R 3 is selected from —R, —halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )N(
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C(( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
  • each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring.
  • Preferred rings formed by R x and R y of formula IIc′′ include a 5-, 6-, or 7-membered unsaturated or partially unsaturated ring having 1-2 heteroatoms, or a partially unsaturated carbocyclo ring, wherein said R x /R y ring is optionally substituted.
  • This provides a bicyclic ring system containing a pyrimidine ring. Examples of preferred pyrimidine ring systems of formula IIc′′ are shown below.
  • More preferred pyrimidine ring systems of formula IIc′′ include IIc′′-B, IIc-D, IIc-E, IIc-J, IIc-P, and IIc-V, most preferably IIc-B, IIc-D, IIc-E, and IIc-J.
  • the ring formed when R x and R y of formula IIc′′ are taken together may be substituted or unsubstituted.
  • Suitable substituents include —R, halo, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —OR, —N(R 4 )—(CH 2 ) 2-4 —N(R 4 ) 2 , —N(R 4 )—(CH 2 ) 2-4 —R, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted
  • R x /R y ring substituents include -halo, —R, —OR, —COR, —CO 2 R, —CON(R 4 ) 2 , —CN, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —NO 2 —N(R 4 ) 2 , —NR 4 COR, —NR 4 SO 2 R, —SO 2 N(R 4 ) 2 wherein R is hydrogen or an optionally substituted C 1-6 aliphatic group.
  • R 2 and R 2′ groups of formula IIc′′ may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IIc′′ compounds having a pyrazole-containing bicyclic ring system:
  • Preferred substituents on the R 2 /R 2′ fused ring of formula IIc′′ include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CN, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O)(C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
  • the (C 1-4 alkyl) group is methyl.
  • preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
  • preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
  • a preferred R 2′ group is hydrogen.
  • Ring D of formula IIc′′ is monocyclic
  • preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Ring D of formula IIc′′ is bicyclic
  • preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
  • T—R 5 or V—Z—R 5 substituents include -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic
  • R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAc, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
  • Preferred formula IIc′′ compounds have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 1-2 heteroatoms selected from oxygen, sulfur, or nitrogen, or a partially unsaturated 6-membered carbocyclo ring, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit, and Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R or —T—W—R 6 and R 2′ is hydrogen; or R 2 and R 2′ are taken together to form an optionally substituted benzo ring; and
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 .
  • More preferred compounds of formula IIc′′ have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x and R y are taken together to form a benzo, pyrido, cyclopento, cyclohexo, cyclohepto, thieno, piperidino, or imidazo ring, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 1 and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered monocyclic ring or an 8-10 membered bicyclic ring selected from an aryl or heteroaryl ring;
  • R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —N(R 4 )—.
  • R x and R y are taken together to form a pyrido, piperidino, or cyclohexo ring, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-Ring D, wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring;
  • R 2 is hydrogen or C 1-4 aliphatic and R 2′ is hydrogen;
  • R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —NH—; and
  • Ring D is substituted by up to three substituents selected from -halo, —CH, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
  • this invention provides a composition comprising a compound of formula IIc, IIc′, or IIc′′, and a pharmaceutically acceptable carrier.
  • Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIc, IIc′, or IIc′′, or a pharmaceutical composition thereof.
  • Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IIc, IIc′, or IIc′′, or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating-or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIc, IIc′, or IIc′′, or a pharmaceutical composition thereof.
  • One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IIc, IIc′, or IIc′′, or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
  • Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IIc, IIc′, or IIc′′, or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a Src-mediated disease with a Src inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIc, IIc′, or IIc′′, or a pharmaceutical composition thereof.
  • Another aspect of the invention relates to inhibiting Src activity in a patient, which method comprises administering to the-patient a compound of formula IIc, IIc′, or IIc′′, or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing an ERK-2-mediated diseases with an ERK-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIc, IIc′, or IIc′′, or a pharmaceutical composition thereof.
  • Another aspect of the invention relates to inhibiting ERK-2 activity in a patient, which method comprises administering to the patient a compound of formula IIc, IIc′, or IIc′′, or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing an AKT-mediated diseases with an AKT inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIc, IIc′, or IIc′′, or a pharmaceutical composition thereof.
  • Another aspect of the invention relates to inhibiting AKT activity in a patient, which method comprises administering to the patient a compound of formula IIc, IIc′, or IIc′′, or a composition comprising said compound.
  • Another method relates to inhibiting Aurora-2, GSK-3, Src, ERK-2, or AKT activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2, GSK-3, Src, ERK-2, or AKT inhibitor of formula IIc, IIc′, or IIc′′, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2, GSK-3, Src, ERK-2, or AKT.
  • Each of the aforementioned methods directed to the inhibition of Aurora-2, GSK-3, Src, ERK-2, or AKT, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of formula IIc, IIc′, or IIc′′, as described above.
  • Another embodiment that is particularly useful for treating Aurora-2-mediated diseases relates to compounds of formula IId:
  • Q′ is selected from —C(R 6′ ) 2 —, 1,2-cyclopropanediyl, 1,2-cyclobutanediyl, or 1,3-cyclobutanediyl;
  • p 1 R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D);
  • Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain, wherein when Q′ is —C(R 6′ ) 2 — a methylene group of said C 1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R 4 )—, —CO—, —CONH—, —NHCO—, —SO 2 —, —SO 2 NH—, —NHSO 2 —, —CO 2 —, —OC(O)—, —OC(O)NH—, or —NHCO 2 —;
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • R 2 and R 2′ are independently selected from —R, —T—W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;
  • R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CH, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )N(
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CH, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
  • each R 6′ is independently selected from hydrogen or a C 1-4 aliphatic group, or two R 6′ on the same carbon atom are taken together to form a 3-6 membered carbocyclic ring;
  • each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring.
  • Preferred rings formed by R x and R y include a 5-, 6-, or 7-membered unsaturated or partially unsaturated ring having 0-2 heteroatoms, wherein said R x /R y ring is optionally substituted.
  • This provides a bicyclic ring system containing a pyrimidine ring. Examples of preferred pyrimidine ring systems of formula IId are shown below.
  • More preferred pyrimidine ring systems of formula IId include IId-A, IId-B, IId-D, IId-E, IId-J, IId-P, and IId-V, most preferably IId-A, IId-B, IId-D, IId-E, and IId-J.
  • the ring formed when R x and R y of formula IId are taken together may be substituted or unsubstituted.
  • Suitable substituents include —R, halo, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —OR, —N(R 4 )—(CH 2 ) 2-4 —N(R 4 ) 2 , —N(R 4 )—(CH 2 ) 2-4 —R, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CH, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C
  • R x /R y ring substituents include -halo, —R, —OR, —COR, —CO 2 R, —CON(R 4 ) 2 , —CN, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, , —NO 2 —N(R 4 ) 2 , —NR 4 COR, —NR 4 SO 2 R, —SO 2 N(R 4 ) 2 wherein R is hydrogen or an optionally substituted C 1-6 aliphatic group.
  • R 2 and R 2 groups of formula IId may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IId compounds having a pyrazole-containing bicyclic ring system:
  • Preferred substituents on the R 2 /R 2′ fused ring of formula IId include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CN, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O)(C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
  • the (C 1-4 alkyl) group is methyl.
  • preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
  • preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
  • a preferred R 2′ group is hydrogen.
  • Ring D of formula IId is monocyclic
  • preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Ring D of formula IId is bicyclic
  • preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
  • T—R 5 or V—Z—R 5 substituents include -halo, —CH, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic
  • R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAc, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
  • Preferred Q′ groups of formula IId include —C(R 6′ ) 2 — or 1,2-cyclopropanediyl, wherein each R 6′ is independently selected from hydrogen or methyl.
  • a more preferred Q′ group is —CH 2 —.
  • Preferred formula IIc compounds have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-2 heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit and wherein said methylene unit is optionally replaced by —O—, —NH—, or —S—;
  • Ring D is a 5-7 membered monocyclic ring or an 8-10 membered bicyclic ring selected from an aryl or heteroaryl ring;
  • R 2 is —R or —T—W—R 6 and R 2′ is hydrogen; or R 2 and R 2′ are taken together to form an optionally substituted benzo ring; and
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 .
  • More preferred compounds of formula IIc have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x and R y are taken together to form a benzo, pyrido, cyclopento, cyclohexo, cyclohepto, thieno, piperidino, or imidazo ring;
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit and wherein said methylene unit is optionally replaced by —O—, and Ring D is a 5-6 membered monocyclic ring or an 8-10 membered bicyclic ring selected from an aryl or heteroaryl ring;
  • R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring;
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —N(R 4 )—; and
  • Q′ is —C(R 6′ ) 2 - or 1,2-cyclopropanediyl, wherein each R 6′ is independently selected from hydrogen or methyl.
  • R x and R y are taken together to form a benzo, pyrido, piperidino, or cyclohexo ring;
  • R 1 is T-Ring D, wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring;
  • R 2 is hydrogen or C 1-4 aliphatic and R 2′ is hydrogen;
  • R 3 is selected from —Rm —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —NH—;
  • Ring D is substituted by up to three substituents selected from -halo, —CH, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
  • this invention provides a composition comprising a compound of formula IId and a pharmaceutically acceptable carrier.
  • Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IId or a pharmaceutical composition thereof.
  • Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IId or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IId or a pharmaceutical composition thereof.
  • One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IId or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
  • Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IId or a composition comprising said compound.
  • Another method relates to inhibiting Aurora-2 or GSK-3 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 or GSK-3 inhibitor of formula IId, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2 or GSK-3.
  • Another embodiment of this invention relates to compounds of formula IIIa:
  • R x and R y are independently selected from T—R 3 or L—Z—R 3 ;
  • R 1 is T-(Ring D);
  • Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • R 2 and R 2′ are independently selected from —R, —T—W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;
  • R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CH, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 ) 2
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CH, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC(( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
  • each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring.
  • R x groups of formula IIIa include hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group such as methyl, ethyl, cyclopropyl, or isopropyl.
  • R y groups of formula IIIa include T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene, L is —O—, —S—, or —N(R 4 )—, —C(R 6 ) 2 O—, —CO— and R 3 is —R, —N(R 4 ) 2 , or —OR.
  • R y groups examples include 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino such as methoxyethylamino, alkoxyalkyl such as methoxymethyl or methoxyethyl, alkyl- or dialkylamino such as ethylamino or dimethylamino, alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl.
  • R 2 and R 2′ groups of formula IIIa may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IIIa compounds having a pyrazole-containing bicyclic ring system:
  • Preferred substituents on the R 2 /R 2′ fused ring of formula IIIa include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CH, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O)(C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
  • the (C 1-4 alkyl) group is methyl.
  • preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
  • preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i -propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
  • a preferred R 2 group is hydrogen.
  • Ring D of formula IIIa is monocyclic
  • preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Ring D of formula IIIa is bicyclic
  • preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
  • T—R 5 or V—Z—R 5 substituents include -halo, —CH, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic
  • R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAc, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
  • Preferred formula IIIa compounds have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x is hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group
  • R y is T—R 3 or L—Z—R 3 , wherein T is a valence bond or a methylene and R 3 is —R, —N(R 4 ), or —OR;
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
  • Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R or —T—W—R 6 and R 2 is hydrogen, or R 2 and R 2′ are taken together to form an optionally substituted benzo ring.
  • More preferred compounds of formula IIIa have one or more, and more preferably all, of the features selected from the group consisting of:
  • R y is T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene and R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl;
  • R 1 is T-(Ring D), wherein T is a valence bond
  • Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
  • L is —O—, —S—, or —N(R 4 )—.
  • R x is hydrogen methyl, ethyl, propyl, cyclopropyl, isopropyl, methylamino or acetimido;
  • R y is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl;
  • R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, —CH, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )SO 2 R, —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 ; and
  • R 2 is hydrogen or a substituted or unsubstituted C 1-6 aliphatic, and L is —O—, —S—, or —NH—.
  • this invention provides a composition comprising a compound of formula IIIa and a pharmaceutically acceptable carrier.
  • Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIIa or a pharmaceutical composition thereof.
  • Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IIIa or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIIa or a pharmaceutical composition thereof.
  • One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IIIa or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
  • Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IIIa or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a Src-mediated disease with a Src inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIIa or a pharmaceutical composition thereof.
  • Another aspect of the invention relates to inhibiting Src activity in a patient, which method comprises administering to the patient a compound of formula IIIa or a composition comprising said compound.
  • Another method relates to inhibiting Aurora-2, GSK-3, or Src activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2, GSK-3, or Src inhibitor of formula IIIa, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2, GSK-3, or Src.
  • Each of the aforementioned methods directed to the inhibition of Aurora-2, GSK-3, or Src, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of formula IIIa, as described above.
  • Another embodiment of this invention relates to compounds of formula IIIb:
  • R x and R y are independently selected from T—R 3 or L—Z—R 3 ;
  • R 1 is T-(Ring D);
  • Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 ) 2 , —C(R 6 ) 2
  • R 2 and R 2 are independently selected from —R, —T—W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2 is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;
  • R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CH, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )N(
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6 -l 0 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CH, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(()O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO 2
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
  • each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring.
  • R x groups of formula IIIb include hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group such as methyl, ethyl, cyclopropyl, or isopropyl.
  • R y groups of formula IIIb include T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene, L is —O—, —S—, or —N(R 4 )—, —C(R 6 ) 2 O—, —CO— and R 3 is —R, —N(R 4 ) 2 , or —OR.
  • R y groups examples include 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino such as methoxyethylamino, alkoxyalkyl such as methoxymethyl or methoxyethyl, alkyl- or dialkylamino such as ethylamino or dimethylamino, alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl.
  • R 2 and R 2′ groups of formula IIIb may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IIIb compounds having a pyrazole-containing bicyclic ring system:
  • Preferred substituents on the R 2 /R 2 fused ring of formula IIIb include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CH, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O)(C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
  • the (C 1-4 alkyl) group is methyl.
  • preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
  • preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
  • a preferred R 2 group is hydrogen.
  • Ring D of formula IIIb is monocyclic
  • preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Ring D of formula IIIb is bicyclic
  • preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
  • preferred T—R 5 or V—Z—R 5 substituents include -halo, —CH, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 cH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocycl
  • R 5 substituents include —Cl, —Br, —F, —CH, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAc, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
  • Preferred formula IIIb compounds have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x is hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group
  • R y is T—R 3 or L—Z—R 3 , wherein T is a valence bond or a methylene and R 3 is —R, —N(R 4 ) 2 , or —OR;
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
  • Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R or —T—W—R 6 and R 2′ is hydrogen, or R 2 and R 2′ are taken together to form an optionally substituted benzo ring.
  • More preferred compounds of formula IIIb have one or more, and more preferably all, of the features selected from the group consisting of:
  • R y is T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene and R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl;
  • R 1 is T-(Ring D), wherein T is a valence bond
  • Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
  • L is —O—, —S—, or —N(R 4 )—.
  • R x is hydrogen methyl, ethyl, propyl, cyclopropyl, isopropyl, methylamino or acetimido;
  • R y is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl;
  • R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, —CH, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )SO 2 R, —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2; and
  • R 2 is hydrogen or a substituted or unsubstituted C 1-6 aliphatic, and L is —O—, —S—, or —NH—.
  • this invention provides a composition comprising a compound of formula IIIb and a pharmaceutically acceptable carrier.
  • Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIIb or a pharmaceutical composition thereof.
  • Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IIIb or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIIb or a pharmaceutical composition thereof.
  • One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IIIb or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
  • Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IIIb or a composition comprising said compound.
  • Another method relates to inhibiting Aurora-2 or GSK-3 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 or GSK-3 inhibitor of formula IIIb, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2 or GSK-3.
  • R x and R y are independently selected from T—R 3 or L—Z—R 3 ;
  • R 1 is T-(Ring D);
  • Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • R 2 and R 2′ are independently selected from —R, —T—W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;
  • R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CH, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )N(
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CH, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC(( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
  • each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring.
  • R x groups of formula IIIc include hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group such as methyl, ethyl, cyclopropyl, or isopropyl.
  • R y groups of formula IIIc include T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene, L is —O—, —S—, or —N(R 4 )—, —C(R 6 ) 2 O—, —CO— and R 3 is —R, —N(R 4 ) 2 , or —OR.
  • R y groups examples include 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino such as methoxyethylamino, alkoxyalkyl such as methoxymethyl or methoxyethyl, alkyl- or dialkylamino such as ethylamino or dimethylamino, alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl.
  • R 2 and R 2′ groups of formula IIIc may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IIIc compounds having a pyrazole-containing bicyclic ring system:
  • Preferred substituents on the R 2 /R 2 fused ring of formula IIIc include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CH, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O)(C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
  • the (C 1-4 alkyl) group is methyl.
  • preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
  • preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
  • a preferred R 2 group is hydrogen.
  • Ring D of formula IIIc is monocyclic
  • preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Ring D of formula IIIc is bicyclic
  • preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
  • T—R 5 or V—Z—R 5 substituents include -halo, —CH, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic
  • R 5 substituents include —Cl, —Br, —F, —CH, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAc, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
  • Preferred formula IIIc compounds have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x is hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group
  • R y is T—R 3 or L—Z—R 3 , wherein T is a valence bond or a methylene and R 3 is —R, —N(R 4 ) 2 , or —OR;
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
  • Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R or —T—W—R 6 and R 2 is hydrogen, or R 2 and R 2′ are taken together to form an optionally substituted benzo ring.
  • More preferred compounds of formula IIIc have one or more, and more preferably all, of the features selected from the group consisting of:
  • R y is T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene and R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl;
  • R 1 is T-(Ring D), wherein T is a valence bond
  • Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
  • L is —O—, —S—, or —N(R 4 )—.
  • R x is hydrogen methyl, ethyl, propyl, cyclopropyl, isopropyl, methylamino or acetimido;
  • R y is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl;
  • R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, —CH, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )SO 2 R, —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 ; and
  • R 2 is hydrogen or a substituted or unsubstituted C 1-6 aliphatic, and L is —O—, —S—, or —NH—.
  • this invention provides a composition comprising a compound of formula IIIc and a pharmaceutically acceptable carrier.
  • Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIIc or a pharmaceutical composition thereof.
  • Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IIIc or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIIc or a pharmaceutical composition thereof.
  • One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IIIc or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
  • Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IIIc or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a Src mediated disease with a Src inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIIc or a pharmaceutical composition thereof.
  • Another aspect of the invention relates to inhibiting Src activity in a patient, which method comprises administering to the patient a compound of formula IIlc or a composition comprising said compound.
  • Another method relates to inhibiting Aurora-2, GSK-3, or Src activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2, GSK-3, or Src inhibitor of formula IIIc, or a pharmaceutical composition thereof, in an amount effective to Aurora-2, GSK-3, or Src.
  • Q′ is selected from —C(R 6′ ) 2 —, 1,2-cyclopropanediyl, 1,2-cyclobutanediyl, or 1,3-cyclobutanediyl;
  • R x and R y are independently selected from T—R 3 or L—Z—R 3 ;
  • R 1 is T-(Ring D);
  • Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain, wherein when Q′ is —C(R 6′ ) 2 — a methylene group of said C 1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R 4 )—, —CO—, —CONH—, —NHCO—, —SO 2 —, —SO 2 NH—, —NHSO 2 —, —CO 2 —, —OC(O)—, —OC(O)NH—, or —NHCO 2 —;
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • R 2 and R 2′ are independently selected from —R, —T—W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;
  • R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )N(
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
  • each R 6′ is independently selected from hydrogen or a C 1-4 aliphatic group, or two R 6′ on the same carbon atom are taken together to form a 3-6 membered carbocyclic ring;
  • each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring.
  • R x groups of formula IIId include hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group such as methyl, ethyl, cyclopropyl, or isopropyl.
  • R y groups of formula IIId include T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene, L is —O—, —S—, or —N(R 4 )—, —C(R 6 ) 2 O—, —CO— and R 3 is —R, —N(R 4 ) 2 , or —OR.
  • R y groups examples include 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino such as methoxyethylamino, alkoxyalkyl such as methoxymethyl or methoxyethyl, alkyl- or dialkylamino such as ethylamino or dimethylamino, alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl.
  • R 2 and R 2′ groups of formula IIId may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IIId compounds having a pyrazole-containing bicyclic ring system:
  • Preferred substituents on the R 2 /R 2′ fused ring of formula IIId include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CN, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O)(C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
  • the (C 1-4 alkyl) group is methyl.
  • preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
  • preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
  • a preferred R 2′ group is hydrogen.
  • Ring D of formula IIId is monocyclic
  • preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Ring D of formula IIId is bicyclic
  • preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
  • preferred T—R 5 or V—Z—R 5 substituents include -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic
  • R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAc, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
  • Preferred Q′ groups of formula IIId include —C(R 6′ ) 2 — or 1,2-cyclopropanediyl, wherein each R 6′ is independently selected from hydrogen or methyl.
  • a more preferred Q′ group is —CH 2 —.
  • Preferred formula IIId compounds have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x is hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group
  • R y is T—R 3 or L—Z—R 3 , wherein T is a valence bond or a methylene and R 3 is —R, —N(R 4 ) 2 , or —OR;
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit and wherein said methylene unit is optionally replaced by —O—, —NH—, or —S—;
  • Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R or —T—W—R 6 and R 2′ is hydrogen, or R 2 and R 2′ are taken together to form an optionally substituted benzo ring.
  • More preferred compounds of formula IIId have one or more, and more preferably all, of the features selected from the group consisting of:
  • R y is T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene and R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl;
  • R 1 is T-(Ring D), wherein T is a valence bond
  • Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring;
  • L is —O—, —S—, or —N(R 4 )—;
  • Q′ is —C(R 6′ ) 2 — or 1,2-cyclopropanediyl, wherein each R 6′ is independently selected from hydrogen or methyl.
  • R x is hydrogen methyl, ethyl, propyl, cyclopropyl, isopropyl, methylamino or acetimido;
  • R y is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl;
  • R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )SO 2 R, —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 ;
  • R 2 is hydrogen or a substituted or unsubstituted C 1-6 aliphatic; and L is —O—, —S—, or —NH—; and
  • this invention provides a composition comprising a compound of formula IIId and a pharmaceutically acceptable carrier.
  • Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIId or a pharmaceutical composition thereof.
  • Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IIId or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIId or a pharmaceutical composition thereof.
  • One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IIId or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
  • Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IIId or a composition comprising said compound.
  • Another method relates to inhibiting Aurora-2 or GSK-3 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 or GSK-3 inhibitor of formula IIId, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2 or GSK-3.
  • Another embodiment of this invention relates to compounds of formula IVa:
  • Z 1 is nitrogen or C—R 8 and Z 2 is nitrogen or CH, wherein one of Z 1 or Z 2 is nitrogen;
  • R x and R y are independently selected from T—R 3 or L—Z—R 3 , or R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D);
  • Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • R 2 and R 2′ are independently selected from —R, —T—W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;
  • R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )N(
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
  • each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring;
  • R 8 is selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 .
  • Preferred rings formed by R x and R y of formula IVa include a 5-, 6-, or 7-membered unsaturated or partially unsaturated ring having 0-2 heteroatoms, wherein said R x /R y ring is optionally substituted. This provides a bicyclic ring system containing a pyridine ring. Preferred pyridine ring systems of formula IVa are shown below.
  • More preferred pyridine ring systems of formula IVa include IVa-A, IVa-B, IVa-D, IVa-E, IVa-J, IVa-P, and IVa-V, most preferably IVa-A, IVa-B, IVa-D, IVa-E, and IVa-J. Even more preferred pyridine ring systems of formula IVa are those described above, wherein Z 1 is nitrogen and Z 2 is CH.
  • R x groups of formula IVa include hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group such as methyl, ethyl, cyclopropyl, or isopropyl.
  • R y groups of formula IVa include T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene, L is —O—, —S—, or —N(R 4 )—, —C(R 6 ) 2 O—, —CO— and R 3 is —R, —N(R 4 ) 2 , or —OR.
  • R y groups examples include 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino such as methoxyethylamino, alkoxyalkyl such as methoxymethyl or methoxyethyl, alkyl- or dialkylamino such as ethylamino or dimethylamino, alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl.
  • the ring formed when the R x and R y groups of formula IVa are taken together may be substituted or unsubstituted.
  • Suitable-substituents include —R, halo, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —OR, —N(R 4 )—(CH 2 ) 2-4 —N(R 4 ) 2 , —N(R 4 )—(CH 2 ) 2-4 —R, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2
  • R x /R y ring substituents include -halo, —R, —OR, —COR, —CO 2 R, —CON(R 4 ) 2 , —CN, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —NO 2 —N(R 4 ) 2 , —NR 4 COR, —NR 4 SO 2 R, —SO 2 N(R 4 ) 2 wherein R is hydrogen or an optionally substituted C 1-6 aliphatic group.
  • R 2 and R 2′ groups of formula IVa may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IVa compounds having a pyrazole-containing bicyclic ring system:
  • Preferred substituents on the R 2 /R 2′ fused ring of formula IVa include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CN, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O)(C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
  • the (C 1-4 alkyl) group is methyl.
  • preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
  • preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
  • a preferred R 2′ group is hydrogen.
  • Ring D of formula IVa is monocyclic
  • preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Ring D of formula IVa is bicyclic
  • preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
  • T—R 5 or V—Z—R 5 substituents include -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic
  • R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAc, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
  • R 8 groups of formula IVa when present, include R, OR, and N(R 4 ) 2 .
  • R 8 include methyl, ethyl, NH 2 , NH 2 CH 2 CH 2 NH, N(CH 3 ) 2 CH 2 CH 2 NH, N(CH 3 ) 2 CH 2 CH 2 O, (piperidin-1-yl)CH 2 CH 2 O, and NH 2 CH 2 CH 2 O.
  • Preferred formula IVa compounds have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x is hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group and R y is T—R 3 or L—Z—R 3 , wherein T is a valence bond or a methylene and R 3 is —R, —N(R 4 ) 2 , or —OR; or R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-2 heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
  • Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R or —T—W—R 6 and R 2′ is hydrogen, or R 2 and R 2′ are taken together to form an optionally substituted benzo ring.
  • More preferred compounds of formula IVa have one or more, and more preferably all, of the features selected from the group consisting of:
  • R y is T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene and R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl; or R x and R y are taken together with their intervening atoms to form a benzo, pyrido, cyclopento, cyclohexo, cyclohepto, thieno, piperidino, or imidazo ring, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D), wherein T is a valence bond, and Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —N(R 4 )—.
  • R x is hydrogen methyl, ethyl, propyl, cyclopropyl, isopropyl, methylamino or acetamido and R y is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl; or R x and R y are taken together with their intervening atoms to form a benzo, pyrido, piperidino, or cyclohexo ring, wherein said ring is optionally substituted with -halo, —R,
  • R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring optionally substituted with one or two groups selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 ;
  • R 2 is hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group, and R 2′ is hydrogen;
  • R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —NH—; and
  • Ring D is substituted by up to three substituents selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
  • this invention provides a composition comprising a compound of formula IVa and a pharmaceutically acceptable carrier.
  • Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IVa or a pharmaceutical composition thereof.
  • Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IVa or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IVa or a pharmaceutical composition thereof.
  • One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IVa or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
  • Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IVa or a composition comprising said compound.
  • Another method relates to inhibiting Aurora-2 or GSK-3 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 or GSK-3 inhibitor of formula IVa, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2 or GSK-3.
  • Z 1 is nitrogen or C—R 8 and Z 2 is nitrogen or CH, wherein one of Z 1 or Z 2 is nitrogen;
  • R x and R y are independently selected from T—R 3 or L—Z—R 3 , or R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D);
  • p 1 Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • R 2 and R 2′ are independently selected from —R, —T—W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;
  • R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )N(
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO 2
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
  • each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring;
  • R 8 is selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 .
  • Preferred rings formed by R x and R y of formula IVb include a 5-, 6-, or 7-membered unsaturated or partially unsaturated ring having 0-2 heteroatoms, wherein said R x /R y ring is optionally substituted. This provides a bicyclic ring system containing a pyrimidine ring. Preferred pyrimidine ring systems of formula IVb are shown below.
  • More preferred pyrimidine ring systems of formula IVb include IVb-A, IVb-B, IVb-D, IVb-E, IVb-J, IVb-P, and IVb-V, most preferably IVb-A, IVb-B, IVb-D, IVb-E, and IVb-J. Even more preferred pyridine ring systems of formula IVb are those described above, wherein Z 1 is nitrogen and Z 2 is CH.
  • R x groups of f ormula IVb include hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group such as methyl, ethyl, cyclopropyl, or isopropyl.
  • R y groups of formula IVb include T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene, L is —O—, —S—, or —N(R 4 )—, —C(R 6 ) 2 O—, —CO— and R 3 is —R, —N(R 4 ) 2 , or —OR.
  • R y groups examples include 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino such as methoxyethylamino, alkoxyalkyl such as methoxymethyl or methoxyethyl, alkyl- or dialkylamino such as ethylamino or dimethylamino, alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl.
  • alkoxyalkylamino such as methoxyethylamino
  • alkoxyalkyl such as methoxymethyl or methoxyethyl
  • the ring formed when the R x and R y groups of formula IVba are taken together may be substituted or unsubstituted.
  • Suitable substituents include —R, halo, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —OR, —N(R 4 )—(CH 2 ) 2-4 —N(R 4 ) 2 , —N(R 4 )—(CH 2 ) 2-4 —R, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally
  • R x /R y ring substituents include -halo, —R, —OR, —COR, —CO 2 R, —CON(R 4 ) 2 , —CN, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —NO 2 —N(R 4 ) 2 , —NR 4 COR, —NR 4 SO 2 R, —SO 2 N(R 4 ) 2 wherein R is hydrogen or an optionally substituted C 1-6 aliphatic group.
  • R 2 and R 2′ groups of formula IVb may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IVb compounds having a pyrazole-containing bicyclic ring system:
  • Preferred substituents on the R 2 /R 2′ fused ring of formula IVb include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CN, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O)(C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
  • the (C 1-4 alkyl) group is methyl.
  • preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
  • preferred R 2 groups include hydrogen, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
  • a preferred R 2′ group is hydrogen.
  • Ring D of formula IVb is monocyclic
  • preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Ring D of formula IVb is bicyclic
  • preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
  • preferred T—R 5 or V—Z—R 5 substituents include -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic
  • R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAc, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
  • R 8 groups of formula IVb when present, include R, OR, and N(R 4 ) 2 .
  • R 8 include methyl, ethyl, NH 2 , NH 2 CH 2 CH 2 NH, N(CH 3 ) 2 CH 2 CH 2 NH, N(CH 3 ) 2 CH 2 CH 2 O, (piperidin-1-yl)CH 2 CH 2 O, and NH 2 CH 2 CH 2 O.
  • Preferred formula IVb compounds have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x is hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group and R y is T—R 3 or L—Z—R 3 , wherein T is a valence bond or a methylene and R 3 is —R, —N(R 4 ) 2 , or —OR; or R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-2 heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
  • Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R or —T—W—R 6 and R 2′ is hydrogen, or R 2 and R 2′ are taken together to form an optionally substituted benzo ring.
  • More preferred compounds of formula IVb have one or more, and more preferably all, of the features selected from the group consisting of:
  • R y is T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene and R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl; or R x and R y are taken together with their intervening atoms to form a benzo, pyrido, cyclopento, cyclohexo, cyclohepto, thieno, piperidino, or imidazo ring, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D), wherein T is a valence bond, and Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —N(R 4 )—.
  • R x is hydrogen methyl, ethyl, propyl, cyclopropyl, isopropyl, methylamino or acetamido and R y is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl; or R x and R y are taken together with their intervening atoms to form a benzo, pyrido, piperidino, or cyclohexo ring, wherein said ring is optionally substituted with -halo, —R,
  • R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring optionally substituted with one or two groups selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 ;
  • R 2 is hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group, and R 2′ is hydrogen;
  • R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —NH—; and
  • Ring D is substituted by up to three substituents selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
  • this invention provides a composition comprising a compound of formula IVb and a pharmaceutically acceptable carrier.
  • Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IVb or a pharmaceutical composition thereof.
  • Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IVb or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IVb or a pharmaceutical composition thereof.
  • One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IVb or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
  • Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IVb or a composition comprising said compound.
  • Another method relates to inhibiting Aurora-2 or GSK-3 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 or GSK-3 inhibitor of formula IVb, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2 or GSK-3.
  • Z 1 is nitrogen or C—R 8 and Z 2 is nitrogen or CH, wherein one of Z 1 or Z 2 is nitrogen;
  • R x and R y are independently selected from T—R 3 or L—Z—R 3 , or R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D);
  • Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • R 2 and R 2′ are independently selected from —R, —T—W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;
  • R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )N(
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
  • each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring;
  • R 8 is selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 .
  • Preferred rings formed by R x and R y of formula IVc include a 5-, 6-, or 7-membered unsaturated or partially unsaturated ring having 0-2 heteroatoms, wherein said R x /R y ring is optionally substituted. This provides a bicyclic ring system containing a pyridine ring. Preferred pyridine ring systems of formula IVc are shown below.
  • More preferred pyridine ring systems of formula IVc include IVc-A, IVc-B, IVc-D, IVc-E, IVc-J, IVc-P, and IVc-V, most preferably IVc-A, IVc-B, IVc-D, IVc-E, and IVc-J. Even more preferred pyridine ring systems of formula IVc are those described above, wherein Z 1 is nitrogen and Z 2 is CH
  • R x groups of formula IVc include hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group such as methyl, ethyl, cyclopropyl, or isopropyl.
  • R y groups of formula IVc include T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene, L is —O—, —S—, or —N(R 4 )—, —C(R 6 ) 2 O—, —CO— and R 3 is —R, —N(R 4 ) 2 , or —OR.
  • R y groups examples include 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino such as methoxyethylamino, alkoxyalkyl such as methoxymethyl or methoxyethyl, alkyl- or dialkylamino such as ethylamino or dimethylamino, alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl.
  • the ring formed when the R x and R y groups of formula IVc are taken together may be substituted or unsubstituted.
  • Suitable substituents include —R, halo, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —OR, —N(R 4 )—(CH 2 ) 2-4 —N(R 4 ) 2 , —N(R 4 )—(CH 2 ) 2-4 —R, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substitute
  • R x /R y ring substituents include -halo, —R, —OR, —COR, —CO 2 R, —CON(R 4 ) 2 , —CN, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —NO 2 —N(R 4 ) 2 , —NR 4 COR, —NR 4 SO 2 R, —SO 2 N(R 4 ) 2 wherein R is hydrogen or an optionally substituted C 1-6 aliphatic group.
  • R 2 and R 2′ groups of formula IVc may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IVc compounds having a pyrazole-containing bicyclic ring system:
  • Preferred substituents on the R 2 /R 2′ fused ring of formula IVc include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CN, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O)(C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
  • the (C 1-4 alkyl) group is methyl.
  • preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
  • preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
  • a preferred R 2 group is hydrogen.
  • Ring D of formula IVc is monocyclic
  • preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Ring D of formula IVc is bicyclic
  • preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
  • T—R 5 or V—Z—R 5 substituents include -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic
  • R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAc, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
  • R 8 groups of formula IVc when present, include R, OR, and N(R 4 ) 2 .
  • R 8 include methyl, ethyl, NH 2 , NH 2 CH 2 CH 2 NH, N(CH 3 ) 2 CH 2 CH 2 NH, N(CH 3 ) 2 CH 2 CH 2 O, (piperidin-1-yl)CH 2 CH 2 O, and NH 2 CH 2 CH 2 O.
  • Preferred formula IVc compounds have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x is hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group and R y is T—R 3 or L—Z—R 3 , wherein T is a valence bond or a methylene and R 3 is —R, —N(R 4 ) 2 , or —OR; or R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-2 heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
  • Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R or —T—W—R 6 and R 2 is hydrogen, or R 2 and R 2′ are taken together to form an optionally substituted benzo ring.
  • More preferred compounds of formula IVc have one or more, and more preferably all, of the features selected from the group consisting of:
  • R y is T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene and R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl; or R x and R y are taken together with their intervening atoms to form a benzo, pyrido, cyclopento, cyclohexo, cyclohepto, thieno, piperidino, or imidazo ring, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ; p 1 (b)
  • R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —N(R 4 )—.
  • R x is hydrogen methyl, ethyl, propyl, cyclopropyl, isopropyl, methylamino or acetamido.
  • R y is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl; or R x and R y are taken together with their intervening atoms to form a benzo, pyrido, piperidino, or cyclohexo ring, wherein said ring is optionally substituted with -halo, —R
  • R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring optionally substituted with one or two groups selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 ;
  • R 2 is hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group, and R 2′ is hydrogen;
  • R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —NH—; and
  • Ring D is substituted by up to three substituents selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
  • this invention provides a composition comprising a compound of formula IVc and a pharmaceutically acceptable carrier.
  • Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IVc or a pharmaceutical composition thereof.
  • Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IVc or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IVc or a pharmaceutical composition thereof.
  • One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IVc or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
  • Another aspect of this invention relates to a method of inhibiting-GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IVc or a composition comprising said compound.
  • Another method relates to inhibiting Aurora-2 or GSK-3 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 or GSK-3 inhibitor of formula IVc, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2 or GSK-3.
  • Z 1 is nitrogen or C—R 8 and Z 2 is nitrogen or CH, wherein one of Z 1 or Z 2 is nitrogen;
  • Q 1 is selected from —C(R 6′ ) 2 —, 1,2-cyclopropanediyl, 1,2-cyclobutanediyl, or 1,3-cyclobutanediyl;
  • R x and R y are independently selected from T—R 3 or L—Z—R 3 , or R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D);
  • Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T—R 5 , or V—Z—R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
  • T is a valence bond or a C 1-4 alkylidene chain, wherein when Q′ is —C(R 6′ ) 2 — a methylene group of said C 1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R 4 )—, —CO—, —CONH—, —NHCO—, —SO 2 —, —SO 2 NH—, —NHSO 2 —, —CO 2 —, —OC(O)—, —OC(O)NH—, or —NHCO 2 —;
  • Z is a C 1-4 alkylidene chain
  • L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • R 2 and R 2′ are independently selected from —R, —T—W—R 6 , or R 2 and R 2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2′ is independently substituted by R 4 ;
  • R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )N(
  • each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
  • each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
  • each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
  • V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
  • W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )
  • each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
  • each R 6′ is independently selected from hydrogen or a C 1-4 aliphatic group, or two R 6′ on the same carbon atom are taken together to form a 3-6 membered carbocyclic ring;
  • each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring;
  • R 8 is selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 .
  • Preferred rings formed by R x and R y of formula IVd include a 5-, 6- , or 7-membered unsaturated or partially unsaturated ring having 0-2 heteroatoms, wherein said R x /R y ring is optionally substituted. This provides a bicyclic ring system containing a pyridine ring. Preferred pyridine ring systems of formula IVa are shown below.
  • More preferred pyridine ring systems of formula IVd include IVd-A, IVd-B, IVd-D, IVd-E, IVd-J, IVd-P, and IVd-V, most preferably IVd-A, IVd-B, IVd-D, IVd-E, and IVd-J. Even more preferred pyridine ring systems of formula IVd include those described above, wherein Z 1 is nitrogen and Z 2 is CH.
  • R x groups of formula IVd include hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group such as methyl, ethyl, cyclopropyl, or isopropyl.
  • R y groups of formula IVd include T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene, L is —O—, —S—, or —N(R 4 )—, —C(R 6 ) 2 O—, —CO and R 3 is —R, —N(R 4 ) 2 , or —OR.
  • R y groups examples include 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino such as methoxyethylamino, alkoxyalkyl such as methoxymethyl or methoxyethyl, alkyl- or dialkylamino such as ethylamino or dimethylamino, alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl.
  • the ring formed when the R x and R y groups of formula IVd are taken together may be substituted or unsubstituted.
  • Suitable substituents include —R, halo, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —OR, —N(R 4 )—(CH 2 ) 2-4 —N(R 4 ) 2 , —N(R 4 )—(CH 2 ) 2-4 —R, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substitute
  • R x /R y ring substituents include -halo, —R, —OR, —COR, —CO 2 R, —CON(R 4 ) 2 , —CN, —O(CH 2 ) 2-4 —N(R 4 ) 2 , —O(CH 2 ) 2-4 —R, —NO 2 —N(R 4 ) 2 , —NR 4 COR, —NR 4 SO 2 R, —SO 2 N(R 4 ) 2 wherein R is hydrogen or an optionally substituted C 1-6 aliphatic group.
  • R 2 and R 2 groups of formula IVd may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
  • Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IVd compounds having a pyrazole-containing bicyclic ring system:
  • Preferred substituents on the R 2 /R 2′ fused ring of formula IVd include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CN, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O)(C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
  • the (C 1-4 alkyl) group is methyl.
  • preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
  • preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
  • a preferred R 2′ group is hydrogen.
  • Ring D of formula IVd is monocyclic
  • preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Ring D of formula IVd is bicyclic
  • preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
  • preferred T—R 5 or V—Z—R 5 substituents include -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic
  • R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAC, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 CH 2 (morpholin-4-yl
  • R 8 groups of formula IVd when present, include R, OR, and N(R 4 ) 2 .
  • R 8 include methyl, ethyl, NH 2 , NH 2 CH 2 CH 2 NH, N(CH 3 ) 2 CH 2 CH 2 NH, N(CH 3 ) 2 CH 2 CH 2 O, (piperidin-1-yl)CH 2 CH 2 O, and NH 2 CH 2 CH 2 O.
  • Preferred Q′ groups of formula IVd include —C(R 6′ ) 2 — or 1,2-cyclopropanediyl, wherein each R 6′ is independently selected from hydrogen or methyl.
  • a more preferred Q′ group is —CH 2 —.
  • Preferred formula IVd compounds have one or more, and more preferably all, of the features selected from the group consisting of:
  • R x is hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group and R y is T—R 3 or L—Z—R 3 ,wherein T is a valence bond or a methylene and R 3 is —R, —N(R 4 ) 2 , or —OR; or R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-6 membered ring having 0-2 heteroatoms selected from oxygen, sulfur, or nitrogen, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit and wherein said methylene unit is optionally replaced by —O—, —NH—, or —S—;
  • Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R or —T—W—R 6 and R 2 is hydrogen, or R 2 and R 2′ are taken together to form an optionally substituted benzo ring.
  • More preferred compounds of formula IVd have one or more, and more preferably all, of the features selected from the group consisting of:
  • R y is T—R 3 or L—Z—R 3 wherein T is a valence bond or a methylene and R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl; or R x and R y are taken together with their intervening atoms to form a benzo, pyrido, cyclopento, cyclohexo, cyclohepto, thieno, piperidino, or imidazo ring, wherein each substitutable ring carbon of said fused ring formed by R x and R y is independently substituted by oxo, T—R 3 , or L—Z—R 3 , and each substitutable ring nitrogen of said ring formed by R x and R y is independently substituted by R 4 ;
  • R 1 is T-(Ring D), wherein T is a valence bond, and Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
  • R 2 is —R and R 2′ is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring;
  • R 3 is selected from —R, -halo, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, or 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —N(R 4 )—; and
  • Q′ is —C(R 6′ ) 2 — or 1,2-cyclopropanediyl, wherein each R 6′ is independently selected from hydrogen or methyl.
  • R x is hydrogen methyl, ethyl, propyl, cyclopropyl, isopropyl, methylamino or acetamido and R y is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl; or R x and R y are taken together with their intervening atoms to form a benzo, pyrido, piperidino, or cyclohexo ring, wherein said ring is optionally substituted with -halo, —R,
  • R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring optionally substituted with one or two groups selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 ;
  • R 2 is hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group, and R 2′ is hydrogen;
  • R 3 is selected from —R, —OR, or —N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is —O—, —S—, or —NH—;
  • Ring D is substituted by up to three substituents selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring; and
  • this invention provides a composition comprising a compound of formula IVd and a pharmaceutically acceptable carrier.
  • Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IVd or a pharmaceutical composition thereof.
  • Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IVd or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IVd or a pharmaceutical composition thereof.
  • One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IVd or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
  • Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IVd or a composition comprising said compound.
  • Another method relates to inhibiting Aurora-2 or GSK-3 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 or GSK-3 inhibitor of formula IVd, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2 or GSK-3.
  • Scheme I above shows a general route for the preparation of the present compounds.
  • the dichlorinated starting material 1 may be prepared using methods similar to the those reported in J. Indian. Chem. Soc., 61, 690-693 (1984) or in J. Med. Chem., 37, 3828-3833 (1994).
  • the reaction of 1 with aminopyrazole (or aminoindazole) 2 in a manner as described in Bioorg. Med. Chem. Lett, 10, 11, 1175-1180, (2000) or in J. Het. Chem, 21, 1161-1167, (1984) provides the versatile monochloro intermediate 3.
  • Conditions for displacing the chloro group of 3 by R 1 —Q will depend on the nature of the Q linker moiety and are generally known in the field.
  • Reagents (a) POCl 3 , Pr 3 N, 110° C.; (b) EtOH, Et 3 N, room temperature.
  • Scheme II above shows an alternative route for the preparation of the present compounds.
  • the starting material 4 may be prepared in a manner similar to that described for analogous compounds. See Chem. Heterocycl. Compd., 35, 7, 818-820 (1999) (where Q is an N-Link), Indian J. Chem. Sect. B, 22, 1, 37-42 (1983) (N-Link), Pestic. Sci, 47, 2, 103-114 (1996) (O-Link), J. Med. Chem., 23, 8, 913-918 (1980) (S-Link), or Pharmazie, 43, 7, 475-476 (1988) (C-Link).
  • the chlorination of 4 provides intermediate 5. See J. Med.
  • Scheme III above shows another alternative route for preparing the present compounds.
  • the starting material 6 may be chlorinated to provide intermediate 7.
  • Displacement of the 4-chloro group in 7 with aminopyrazole (or aminoindazole) 2 gives intermediate 8 which, upon oxidation of the methylsulfanyl group, provides the methylsulfone 9.
  • the methylsulfonyl group of 9 may be displaced readily with R 1 —QH to give the desired product I. See J. Am. Chem. Soc., 81, 5997-6006 (1959) (where Q is an N-Link)or in Bioorg. Med. Chem. Lett., 10, 8, 821-826 (2000) (S-Link).
  • Scheme IV above shows a general route for the preparation of the present compounds wherein R y is a group attached to the pyrimidine core via a nitrogen, oxygen or sulfur heteroatom.
  • the starting 4,6-dihydroxy-2-methylsulfanylpyrimidine 10 may be prepared as described in J. Med. Chem., 27, 12, 1621-1629 (1984).
  • the chloro groups of intermediate 11 may be displaced sequentially with aminopyrazole (or aminoindazole) 2 and then with another amine (or alcohol or thiol) following procedures similar to those reported in U.S. Pat. No. 2,585,906 (ICI, 1949).
  • the methylsulfanyl group of 13 may then be oxidized to provide the methylsulfone 14. Displacement of the methylsulfonyl group of 14 gives the desired product II.
  • Scheme V above shows general routes for the preparation of compounds of formulae IVa, IVb, IVc, and IVd. Steps (a) and (b) are analogous to the corresponding steps described in Scheme I above. See Indian J. Chem. Sect. B, 34, 9, 1995, 778-790; J. Chem. Soc., 1947, 899-905; J. Chem. Soc., 34, 9, 1948, 777-782; and Indian J. Chem., 1967, 467-470.
  • Scheme VI above shows a general route for preparing the aryl guanidine intermediate used to prepare compounds where Q is —C(R 6′ ) 2 —.
  • the mono- or bis-alkylation of 19 at step (a) to prepare compound 20 can be achieved by using methods substantially similar to those described by Jeffery, J. E., et al, J. Chem Soc , Perkin Trans 1, 1996 (21) 2583-2589; Gnecco, D., et al, Org Prep Proced Int, 1996, 28 (4), 478-480; Fedorynski, M.
  • step (b) to prepare compound 21 from compound 20 can be achieved by using methods substantially similar to those described by Moss, R., et al, Tetrahedron Lett, 1995, (48), 8761-8764 and Garigipati, R., Tetrahedron Lett, 1990, (14), 1969-1972.
  • Scheme VII above shows a general method that may be used to prepare compounds of formula II wherein Q is 1,2-cyclopropanediyl.
  • Compound 26 may then be used to prepare the desired amino-pyrazole compounds using the methods described above at Scheme I step (b).
  • Method B Sodium hydride (45 mg, 1.12 mmol) in THF (2 mL) is treated with 3-methoxyphenol (0.94 g, 7.6 mmol) and the reaction mixture is stirred until effervescence ceases.
  • the THF is removed in vacuo and the above-prepared (2-chloroquinazolin-4-yl)-(5-methyl-2H-pyrazol-3-yl)-amine (150 mg, 0.51 mmol)) is added.
  • the reaction mixture is stirred at 100° C. for 20 h, then poured into aqueous K 2 CO 3 and stirred for 2 h at room temperature. The solid that forms is collected and re-crystallized from ethanol to give the product [2-(3-methoxyphenoxy)-quinazolin-4-yl]-(5-methyl-2H-pyrazol-3-yl)-amine.
  • Method G A solution of (5-cyclopropyl-2H-pyrazol-3-yl)-[2-(3-methoxycarbonylphenylsulfanyl)-quinazolin-4-yl]-amine (110 mg, 0.26 mmol) in a mixture of THF/water (1/1, 10 mL) is treated with 1M LiOH (0.75 mL, 0.75 mmol). The mixture is stirred for 20 hours at room temperature and then neutralized with 1M HCl (0.75 mL, 0.75 mmol).

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
US10/026,966 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors Abandoned US20030105090A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/026,966 US20030105090A1 (en) 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors
US10/736,426 US7087603B2 (en) 2000-12-21 2003-12-15 Pyrazole compounds useful as protein kinase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25788700P 2000-12-21 2000-12-21
US28694901P 2001-04-27 2001-04-27
US10/026,966 US20030105090A1 (en) 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/736,426 Continuation US7087603B2 (en) 2000-12-21 2003-12-15 Pyrazole compounds useful as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
US20030105090A1 true US20030105090A1 (en) 2003-06-05

Family

ID=26946273

Family Applications (16)

Application Number Title Priority Date Filing Date
US10/026,966 Abandoned US20030105090A1 (en) 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors
US10/025,164 Expired - Fee Related US6664247B2 (en) 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors
US10/027,001 Expired - Fee Related US6653301B2 (en) 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors
US10/026,975 Expired - Fee Related US6653300B2 (en) 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors
US10/026,967 Expired - Fee Related US6989385B2 (en) 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors
US10/026,992 Expired - Fee Related US7625913B2 (en) 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors
US10/034,683 Expired - Fee Related US6656939B2 (en) 2000-12-21 2001-12-20 Pyrazole compounds useful as protein kinase inhibitors
US10/034,019 Expired - Fee Related US6727251B2 (en) 2000-12-21 2001-12-20 Pyrazole compounds useful as protein kinase inhibitors
US10/632,428 Expired - Fee Related US7531536B2 (en) 2000-12-21 2003-08-01 Pyrazole compounds useful as protein kinase inhibitors
US10/722,374 Abandoned US20040157893A1 (en) 2000-12-21 2003-11-25 Pyrazole compounds useful as protein kinase inhibitors
US10/736,426 Expired - Fee Related US7087603B2 (en) 2000-12-21 2003-12-15 Pyrazole compounds useful as protein kinase inhibitors
US10/775,699 Expired - Fee Related US7427681B2 (en) 2000-12-21 2004-02-10 Pyrazole compounds useful as protein kinase inhibitors
US12/109,598 Expired - Fee Related US8304414B2 (en) 2000-12-21 2008-04-25 Pyrazole compounds useful as protein kinase inhibitors
US12/545,347 Expired - Fee Related US7982037B2 (en) 2000-12-21 2009-08-21 Pyrazole compounds useful as protein kinase inhibitors
US13/631,488 Expired - Fee Related US8697698B2 (en) 2000-12-21 2012-09-28 Pyrazole compounds useful as protein kinase inhibitors
US14/139,889 Abandoned US20140187772A1 (en) 2000-12-21 2013-12-24 Pyrazole compounds useful as protein kinase inhibitors

Family Applications After (15)

Application Number Title Priority Date Filing Date
US10/025,164 Expired - Fee Related US6664247B2 (en) 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors
US10/027,001 Expired - Fee Related US6653301B2 (en) 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors
US10/026,975 Expired - Fee Related US6653300B2 (en) 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors
US10/026,967 Expired - Fee Related US6989385B2 (en) 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors
US10/026,992 Expired - Fee Related US7625913B2 (en) 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors
US10/034,683 Expired - Fee Related US6656939B2 (en) 2000-12-21 2001-12-20 Pyrazole compounds useful as protein kinase inhibitors
US10/034,019 Expired - Fee Related US6727251B2 (en) 2000-12-21 2001-12-20 Pyrazole compounds useful as protein kinase inhibitors
US10/632,428 Expired - Fee Related US7531536B2 (en) 2000-12-21 2003-08-01 Pyrazole compounds useful as protein kinase inhibitors
US10/722,374 Abandoned US20040157893A1 (en) 2000-12-21 2003-11-25 Pyrazole compounds useful as protein kinase inhibitors
US10/736,426 Expired - Fee Related US7087603B2 (en) 2000-12-21 2003-12-15 Pyrazole compounds useful as protein kinase inhibitors
US10/775,699 Expired - Fee Related US7427681B2 (en) 2000-12-21 2004-02-10 Pyrazole compounds useful as protein kinase inhibitors
US12/109,598 Expired - Fee Related US8304414B2 (en) 2000-12-21 2008-04-25 Pyrazole compounds useful as protein kinase inhibitors
US12/545,347 Expired - Fee Related US7982037B2 (en) 2000-12-21 2009-08-21 Pyrazole compounds useful as protein kinase inhibitors
US13/631,488 Expired - Fee Related US8697698B2 (en) 2000-12-21 2012-09-28 Pyrazole compounds useful as protein kinase inhibitors
US14/139,889 Abandoned US20140187772A1 (en) 2000-12-21 2013-12-24 Pyrazole compounds useful as protein kinase inhibitors

Country Status (27)

Country Link
US (16) US20030105090A1 (OSRAM)
EP (10) EP1345927B1 (OSRAM)
JP (19) JP4160389B2 (OSRAM)
KR (8) KR20030061858A (OSRAM)
CN (6) CN100408573C (OSRAM)
AP (2) AP2003002825A0 (OSRAM)
AR (4) AR040925A1 (OSRAM)
AT (9) ATE340172T1 (OSRAM)
AU (7) AU2001297619B2 (OSRAM)
BR (2) BR0116493A (OSRAM)
CA (8) CA2432223C (OSRAM)
CY (1) CY1106297T1 (OSRAM)
DE (8) DE60119774T2 (OSRAM)
DK (3) DK1345922T3 (OSRAM)
ES (7) ES2265446T3 (OSRAM)
HU (5) HUP0400639A3 (OSRAM)
IL (8) IL156389A0 (OSRAM)
MX (8) MXPA03005609A (OSRAM)
MY (1) MY140377A (OSRAM)
NO (5) NO328537B1 (OSRAM)
NZ (8) NZ526473A (OSRAM)
PL (2) PL210066B1 (OSRAM)
PT (3) PT1345922E (OSRAM)
RU (1) RU2355688C2 (OSRAM)
SI (2) SI1353916T1 (OSRAM)
TW (2) TWI290551B (OSRAM)
WO (8) WO2002068415A1 (OSRAM)

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064982A1 (en) * 2000-09-15 2003-04-03 Robert Davies Pyrazole compounds useful as protein kinase inhibitors
US20040116454A1 (en) * 2000-09-15 2004-06-17 Robert Davies Pyrazole compounds useful as protein kinase inhibitors
US20040157893A1 (en) * 2000-12-21 2004-08-12 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US20050153966A1 (en) * 2003-12-19 2005-07-14 Syrrx, Inc. Kinase inhibitors
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
US20060041137A1 (en) * 2004-08-18 2006-02-23 Takeda San Diego, Inc. Kinase inhibitors
US20060084650A1 (en) * 2004-10-15 2006-04-20 Qing Dong Kinase inhibitors
US20060270660A1 (en) * 2002-06-20 2006-11-30 Vertex Pharmaceuticals Incorporated Processes for preparing substituted pyrimidines
US20070117816A1 (en) * 2005-10-07 2007-05-24 Brown Jason W Kinase inhibitors
US20070142368A1 (en) * 2005-09-30 2007-06-21 Xiao-Yi Xiao Substituted pyrazole compounds
US20070173516A1 (en) * 2005-08-18 2007-07-26 Michael Mortimore Pyrazine kinase inhibitors
US20070190634A1 (en) * 2002-03-15 2007-08-16 David Bebbington Compositions useful as inhibitors of protein kinases
US20070208044A1 (en) * 2003-07-03 2007-09-06 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
US20070249031A1 (en) * 2005-11-03 2007-10-25 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US20070270444A1 (en) * 2000-09-15 2007-11-22 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US20070270420A1 (en) * 2002-02-06 2007-11-22 Harbeson Scott L Heteroaryl compounds useful as inhibitors of gsk-3
US20080004302A1 (en) * 2006-06-30 2008-01-03 Astrazeneca Ab Novel Compounds
US20080176872A1 (en) * 2005-02-16 2008-07-24 Astrazeneca Ab Chemical Compounds
US20090029992A1 (en) * 2007-06-11 2009-01-29 Agoston Gregory E Substituted pyrazole compounds
US7491730B2 (en) 2002-08-02 2009-02-17 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of GSK-3
US20090131463A1 (en) * 2001-12-07 2009-05-21 Astrazeneca Ab Novel compounds
US20090156557A1 (en) * 2007-04-18 2009-06-18 Takeda San Diego, Inc. Kinase inhibitors
US20090325968A1 (en) * 2003-02-06 2009-12-31 Vertex Pharmaceuticals Incorporated Compositions Useful as Inhibitors of Protein Kinases
US20100022507A1 (en) * 2006-12-19 2010-01-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US20100022502A1 (en) * 2006-11-02 2010-01-28 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
US20100081657A1 (en) * 2003-12-04 2010-04-01 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
US20100160325A1 (en) * 2005-10-28 2010-06-24 Astrazeneca Ab 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US20100184980A1 (en) * 2007-07-31 2010-07-22 Juan-Miguel Jimenez Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof
US20100197761A1 (en) * 2006-06-27 2010-08-05 Tsuneo Yasuma Fused cyclic compounds
US20100204246A1 (en) * 2007-04-18 2010-08-12 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo (4,5-b) pyridine derivatives and their use for the treatment of cancer
US20100210648A1 (en) * 2005-05-16 2010-08-19 Astrazeneca R&D Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
US20100215772A1 (en) * 2007-05-02 2010-08-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US20100317641A1 (en) * 2007-05-02 2010-12-16 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
US20100324040A1 (en) * 2007-05-04 2010-12-23 Astrazeneca Ab 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyrazol-3-yl) -3h-imidazo[4,5-b] pyridin-5- amine derivatives and their use for the treatment of cancer
US20110021559A1 (en) * 2007-03-09 2011-01-27 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
US20110020377A1 (en) * 2007-03-09 2011-01-27 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US20110020376A1 (en) * 2007-03-09 2011-01-27 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US20110046104A1 (en) * 2007-05-02 2011-02-24 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US20110060013A1 (en) * 2007-05-24 2011-03-10 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
US20110183954A1 (en) * 2008-06-11 2011-07-28 Astrazeneca Ab Tricyclic 2,4-diamino-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
US7989462B2 (en) 2003-07-03 2011-08-02 Myrexis, Inc. 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20110201628A1 (en) * 2008-09-30 2011-08-18 Astrazeneca Ab Heterocyclic jak kinase inhibitors
US20110236478A1 (en) * 2008-09-03 2011-09-29 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
US8153630B2 (en) 2004-11-17 2012-04-10 Miikana Therapeutics, Inc. Kinase inhibitors
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US8278450B2 (en) 2007-04-18 2012-10-02 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US8354420B2 (en) 2010-06-04 2013-01-15 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 inhibitors
US8455507B2 (en) 2007-04-13 2013-06-04 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8633207B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
US8637537B2 (en) 2011-08-25 2014-01-28 Genentech, Inc. Serine/threonine kinase inhibitors
US8815882B2 (en) 2010-11-10 2014-08-26 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
US8815877B2 (en) 2011-12-22 2014-08-26 Genentech, Inc. Serine/threonine kinase inhibitors
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
US9006241B2 (en) 2011-03-24 2015-04-14 Noviga Research Ab Pyrimidine derivatives

Families Citing this family (324)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982260B1 (en) 1999-11-22 2006-01-03 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
ATE407132T1 (de) * 2000-12-05 2008-09-15 Vertex Pharma Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen
EP1370553B1 (en) * 2001-03-23 2006-05-10 Bayer Corporation Rho-kinase inhibitors
EP1379251B1 (en) 2001-04-10 2008-07-09 Merck & Co., Inc. Inhibitors of akt activity
US7105667B2 (en) * 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003026664A1 (en) * 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
PL368347A1 (en) 2001-09-26 2005-03-21 Pharmacia Italia S.P.A. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
DE60325551D1 (de) * 2002-01-10 2009-02-12 Hoffmann La Roche Verwendung eines gsk-3beta-hemmers bei der herstellung eines arzneimittel zur erhöhung der knochenbildung
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7091343B2 (en) 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2003225800A1 (en) * 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
AU2003223467B2 (en) 2002-04-08 2007-10-04 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AU2003242252A1 (en) 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
AU2003261204A1 (en) * 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
RS51752B (sr) 2002-07-29 2011-12-31 Rigel Pharmaceuticals Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina
SI1532145T1 (sl) * 2002-08-02 2007-02-28 Vertex Pharma Pirazolni sestavki, koristni kot inhibitorji GSK-3
EP1537087B1 (fr) * 2002-09-05 2012-11-28 Aventis Pharma S.A. Derives de 3-aminoindazole comme inhibiteurs de kinase et compositions pharmaceutiques les renfermant
FR2844267B1 (fr) * 2002-09-05 2008-02-15 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
AU2003255482A1 (en) * 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
NZ539211A (en) * 2002-10-04 2008-05-30 Prana Biotechnology Ltd Neurologically-active compounds
KR100490893B1 (ko) * 2002-10-11 2005-05-23 (주) 비엔씨바이오팜 2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
US7309701B2 (en) 2002-11-19 2007-12-18 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
US7462613B2 (en) 2002-11-19 2008-12-09 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
MXPA05005477A (es) 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
EP1644338A1 (en) * 2003-04-01 2006-04-12 Aponetics AG 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
EP1633740B1 (en) * 2003-06-19 2011-11-09 GlaxoSmithKline LLC 5-(acylamino)indazole derivatives as kinase inhibitors
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0315966D0 (en) * 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
NZ544756A (en) 2003-07-22 2009-09-25 Astex Therapeutics Ltd 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
HRP20130602T1 (en) 2003-07-30 2013-07-31 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
JP2007500179A (ja) * 2003-07-30 2007-01-11 サイクラセル・リミテッド キナーゼ阻害剤としての２−アミノフェニル−４−フェニルピリミジン
US20060024690A1 (en) * 2003-09-19 2006-02-02 Kao H P Normalization of data using controls
US7417726B2 (en) * 2003-09-19 2008-08-26 Applied Biosystems Inc. Normalization of data using controls
US20050221357A1 (en) * 2003-09-19 2005-10-06 Mark Shannon Normalization of gene expression data
US20050124562A1 (en) * 2003-09-23 2005-06-09 Joseph Guiles Bis-quinazoline compounds for the treatment of bacterial infections
KR20060123164A (ko) 2003-10-17 2006-12-01 아스트라제네카 아베 암 치료에 사용하기 위한 4-(피라졸-3-일아미노)피리미딘유도체
KR20060123452A (ko) * 2003-12-09 2006-12-01 버텍스 파마슈티칼스 인코포레이티드 나프티리딘 유도체 및 무스카린 수용체의 조절자로서의이의 용도
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
AU2005212438A1 (en) * 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20080050314A1 (en) * 2004-02-26 2008-02-28 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated With Glycogen Synthase Kinase 3 Beta (Gsk3b)
JP4875978B2 (ja) * 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
US7897607B2 (en) * 2004-04-07 2011-03-01 Takeda Pharmaceutical Company Limited Cyclic compounds
US20090227648A1 (en) * 2004-04-21 2009-09-10 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
US7880000B2 (en) * 2004-05-07 2011-02-01 Amgen Inc. Protein kinase modulators and method of use
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
US20050255485A1 (en) * 2004-05-14 2005-11-17 Livak Kenneth J Detection of gene duplications
AU2012200416B2 (en) * 2004-05-14 2014-07-31 Millennium Pharmaceuticals, Inc. "Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase"
RU2006144448A (ru) * 2004-05-14 2008-06-20 Вертекс Фармасьютикалз Пролекарства пирролилпиримидиновых ингибиторов протеинкиназы erk
JP4467616B2 (ja) * 2004-05-14 2010-05-26 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Ａｕｒｏｒａキナーゼの阻害により有糸分裂の進行を阻止するための化合物および方法
DK1905773T3 (da) * 2004-05-14 2012-10-15 Millennium Pharm Inc Forbindelser og fremgangsmåder til hæmning af mitotisk progression ved hæmning af aurorakinase
WO2005112923A2 (en) * 2004-05-20 2005-12-01 Bayer Pharmaceuticals Corporation 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
EP1756673A1 (en) * 2004-05-27 2007-02-28 E.I.Du pont de nemours and company Developer for a photopolymer protective layer
EP1765325A4 (en) * 2004-07-01 2009-08-12 Synta Pharmaceuticals Corp HETEROARYL COMPOUNDS SUBSTITUTED IN 2
JP2008505907A (ja) * 2004-07-06 2008-02-28 アンジオン バイオメディカ コーポレイション 癌治療を目的として肝細胞増殖因子およびｃ−ｍｅｔ活性を調整するキナゾリンモジュレーター
TW200624431A (en) * 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
BRPI0516746A (pt) * 2004-09-30 2008-09-23 Tibotec Pharm Ltd 5-heterociclil pirimidinas para inibição de hiv
RU2410379C2 (ru) * 2004-09-30 2011-01-27 Тиботек Фармасьютикалз Лтд. 5-замещенные пиримидины, ингибирующие вич
EP1797048B1 (en) * 2004-09-30 2011-08-17 Tibotec Pharmaceuticals Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
BRPI0518068A (pt) * 2004-10-29 2008-10-28 Banyu Pharma Co Ltd composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada
JP2008519034A (ja) 2004-11-03 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネル調節剤としてのピリミジン誘導体および使用方法
DK1814878T3 (da) 2004-11-24 2012-05-07 Rigel Pharmaceuticals Inc Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
JP2008525422A (ja) * 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
EP1833819A1 (en) 2004-12-30 2007-09-19 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
CN101146796A (zh) * 2005-01-26 2008-03-19 先灵公司 作为蛋白激酶抑制剂用于治疗癌症的3-(吲唑-5-基)-(1,2,4)三嗪衍生物及相关化合物
DK2383268T3 (en) * 2005-02-04 2015-09-14 Astrazeneca Ab PYRAZOLYLAMINOPYRIDINDERIVATER useful as kinase inhibitors
AU2006215394B2 (en) * 2005-02-16 2009-10-08 Astrazeneca Ab Chemical compounds
CN101500574A (zh) * 2005-03-15 2009-08-05 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
EP1863797A1 (en) * 2005-03-23 2007-12-12 AstraZeneca AB 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY
US7402596B2 (en) * 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US20080167297A1 (en) * 2005-04-05 2008-07-10 Astrazeneca Ab Pyrimidine Derivatives for Use as Anticancer Agents
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds
CA2603204A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
JP2008540335A (ja) * 2005-04-27 2008-11-20 アストラゼネカ・アクチエボラーグ ピラゾリル・ピリミジン誘導体の疼痛治療における使用
US7928126B2 (en) 2005-04-28 2011-04-19 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
WO2006117212A2 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
MX2007013595A (es) 2005-05-04 2008-01-24 Renovis Inc Compuestos heterociclicos fusionados y composiciones y usos de estos.
JP2008540391A (ja) * 2005-05-05 2008-11-20 アストラゼネカ アクチボラグ ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
CA2608367C (en) 2005-06-08 2014-08-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
EA015890B1 (ru) 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Производные пиримидина
EP1746096A1 (en) 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
WO2007023382A2 (en) * 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
UA96427C2 (en) * 2005-09-30 2011-11-10 Мийкана Терапьютикс, Инк. Substituted pyrazole compounds
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP5137207B2 (ja) * 2005-11-01 2013-02-06 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化因子
AU2006315334B2 (en) * 2005-11-16 2011-05-19 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
WO2007081978A2 (en) * 2006-01-11 2007-07-19 Angion Biomedica Corporation Modulators of hepatocyte growth factor / c-met activity
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
DE602007009932D1 (de) 2006-02-16 2010-12-02 Schering Corp Pyrrolidin-derivate als erk-hemmer
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
ES2465666T3 (es) * 2006-03-30 2014-06-06 Janssen R&D Ireland Pirimidinas 5-amido-sustituidas inhibidoras del HIV
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
JP2009532440A (ja) 2006-04-07 2009-09-10 ノバルティス アクチエンゲゼルシャフト ａ）ピリミジルアミノベンズアミド化合物、およびｂ）Ｔｈｒ３１５Ｉｌｅキナーゼ阻害剤を含む、組合せ剤
EP2012789B1 (en) 2006-04-14 2013-09-25 Prana Biotechnology Limited Method of treatment of age-related macular degeneration (AMD)
EP2017279B1 (en) * 2006-04-27 2013-09-04 Msd K.K. Aminopyrimidine derivatives having aurora-a-selective inhibitory activity
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
WO2008001115A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
WO2008001101A2 (en) * 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
EP2036894A4 (en) * 2006-06-30 2011-01-12 Kyowa Hakko Kirin Co Ltd AURORA INHIBITOR
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
JP2010500352A (ja) * 2006-08-09 2010-01-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 有糸分裂の進行を阻止するためのピリドベンゾアゼピン化合物および方法
US7832809B2 (en) * 2006-08-11 2010-11-16 Schlumberger Technology Corporation Degradation assembly shield
JP2008081492A (ja) * 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
WO2008053812A1 (en) * 2006-10-27 2008-05-08 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and medicinal use thereof
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CA2674178C (en) * 2006-12-29 2015-11-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 6-substituted pyrimidines
ES2618057T3 (es) * 2006-12-29 2017-06-20 Janssen Sciences Ireland Uc Pirimidinas 5,6-sustituidas inhibidoras del VIH
US8173647B2 (en) 2007-02-06 2012-05-08 Gordana Atallah PI 3-kinase inhibitors and methods of their use
WO2008111441A1 (ja) 2007-03-05 2008-09-18 Kyowa Hakko Kirin Co., Ltd. 医薬組成物
JP2010522194A (ja) * 2007-03-20 2010-07-01 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害薬として有用なアミノピリミジン
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
ES2593486T3 (es) 2007-04-18 2016-12-09 Pfizer Products Inc. Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo
ES2369596T3 (es) * 2007-05-04 2011-12-02 Astrazeneca Ab Derivados de amino-tiazolil-pirimidina y su uso para el tratamiento del cáncer.
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
JP2010532756A (ja) * 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
WO2009007753A2 (en) * 2007-07-11 2009-01-15 Astrazeneca Ab 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
AU2008279097B2 (en) * 2007-07-25 2013-05-02 Bristol-Myers Squibb Company Triazine kinase inhibitors
WO2009013545A2 (en) * 2007-07-26 2009-01-29 Astrazeneca Ab Chemical compounds
TW200906818A (en) * 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009027736A2 (en) * 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
ES2569734T3 (es) 2007-09-21 2016-05-12 Array Biopharma, Inc. Derivados de piridin-2-il-tiourea y de piridin-2-il-amina como intermedios para la preparación de piridin-2-il-amino-1,2,4-tiadiazoles activadores de la glucocinasa
CA2702265C (en) 2007-10-11 2014-12-02 Smithkline Beecham Corporation Novel seh inhibitors and their use
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
JP5276676B2 (ja) * 2008-02-21 2013-08-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である化合物
ES2531398T3 (es) * 2008-02-22 2015-03-13 Msd Kk Nuevos derivados de aminopiridina que tienen una acción inhibidora selectiva de Aurora A
WO2009131598A1 (en) 2008-04-21 2009-10-29 Taigen Biotechnology Co., Ltd. Heterocyclic compounds
US8844033B2 (en) 2008-05-27 2014-09-23 The Trustees Of Columbia University In The City Of New York Systems, methods, and media for detecting network anomalies using a trained probabilistic model
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
PE20110403A1 (es) * 2008-07-31 2011-07-04 Genentech Inc Compuestos biciclicos fusionados de pirimidina en el tratamiento del cancer
MX2011002484A (es) * 2008-09-05 2011-09-26 Avila Therapeutics Inc Algoritmo para diseñar inhibidores irreversibles.
CN104230901A (zh) * 2008-09-15 2014-12-24 加利福尼亚大学董事会 用于调节ire1、src和abl活性的方法和组合物
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
WO2010056758A1 (en) * 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
TW201021855A (en) 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
US8524707B2 (en) * 2008-12-19 2013-09-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
BRPI0923579A2 (pt) 2008-12-22 2020-01-14 Millennium Pharm Inc combinação de inibidores de aurora quinase e anticorpos anti-cd20
WO2010072155A1 (zh) * 2008-12-26 2010-07-01 复旦大学 一种嘧啶类衍生物及其制备方法和用途
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN105601619A (zh) * 2009-02-27 2016-05-25 埃姆比特生物科学公司 调控jak激酶的喹唑啉衍生物和其使用方法
CA2660962A1 (en) 2009-03-31 2010-09-30 Astellas Pharma Inc. Novel pharmaceutical composition for treatment of schizophrenia
US8399663B2 (en) 2009-04-03 2013-03-19 Astellas Pharma Inc. Salt of 1,3,5-triazine-2,4,6-triamine derivative
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
EP2440052A4 (en) * 2009-06-08 2013-01-23 Abraxis Bioscience Llc TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
BRPI1010881A2 (pt) * 2009-06-08 2016-05-31 California Capital Equity Llc derivados de triazina e suas aplicações terapêuticas.
CN102573481A (zh) * 2009-06-09 2012-07-11 加利福尼亚资本权益有限责任公司 脲基苯基取代的三嗪衍生物及其治疗应用
AU2010258993B2 (en) * 2009-06-09 2014-07-31 Nantbio, Inc. Styryl-triazine derivatives and their therapeutical applications
CN102573480B (zh) * 2009-06-09 2015-06-10 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
KR20120026612A (ko) * 2009-06-09 2012-03-19 아브락시스 바이오사이언스, 엘엘씨 벤질 치환 트리아진 유도체와 이들의 치료적 용도
WO2010146133A1 (en) * 2009-06-18 2010-12-23 Cellzome Limited Heterocyclylaminopyrimidines as kinase inhibitors
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
BR112012003973A2 (pt) 2009-08-26 2015-09-08 Sanofi Sa hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso
NZ620174A (en) 2009-09-16 2016-08-26 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
CN105193469B (zh) * 2009-11-13 2018-12-04 直观外科手术操作公司 具有复设的闭合机构的末端执行器
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
EP2519664A4 (en) 2009-12-30 2014-03-12 Avila Therapeutics Inc LIGAND-RELATED COVALENTS MODIFYING A PROTEIN
SA111320200B1 (ar) * 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
WO2011103089A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130059830A1 (en) * 2010-05-20 2013-03-07 Fa-Xiang Ding Novel prolylcarboxypeptidase inhibitors
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
ES2674747T3 (es) 2010-07-29 2018-07-03 Oryzon Genomics, S.A. Inhibidores de demetilasa LSD1 basados en arilciclopropilamina y sus usos médicos
EP2611502A1 (en) * 2010-09-01 2013-07-10 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
US8633209B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
WO2012030917A1 (en) * 2010-09-01 2012-03-08 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
EP2611794A1 (en) * 2010-09-01 2013-07-10 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
US20130296363A1 (en) * 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
WO2012030910A1 (en) * 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PH12014500638A1 (en) * 2011-09-22 2017-08-09 Pfizer Pyrrolopyrimidine and purine derivatives
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TWI547493B (zh) 2011-09-27 2016-09-01 諾華公司 作為突變ｉｄｈ之抑制劑之３－嘧啶－４－基－唑啶－２－酮
EP3569598A1 (en) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
US9447051B2 (en) * 2012-02-17 2016-09-20 Abbvie Inc. Diaminopyrimidines and uses thereof
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
JP6120941B2 (ja) 2012-03-16 2017-04-26 アクシキン ファーマシューティカルズ インコーポレーテッド ３，５−ジアミノピラゾールキナーゼ阻害剤
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
CA2875990A1 (en) * 2012-05-24 2013-11-28 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
AU2013289615B2 (en) * 2012-07-10 2017-06-08 Ares Trading S.A. Pyrimidine pyrazolyl derivatives
WO2014046129A1 (ja) * 2012-09-19 2014-03-27 大鵬薬品工業株式会社 溶出性及び／又は吸収性が改善された経口投与用医薬組成物
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN103202843B (zh) * 2012-12-31 2015-04-29 刘强 一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗癌症的药物中的用途
CN103059002B (zh) * 2012-12-31 2015-04-22 中山大学 具有Aurora激酶抑制活性的嘧啶衍生物及其制备方法以及应用
CN103191120B (zh) * 2012-12-31 2015-11-25 刘强 一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗肿瘤的药物中的用途
CN103910716A (zh) * 2013-01-07 2014-07-09 华东理工大学 2,4-二取代-环烷基[d]嘧啶类化合物及其用途
JP6360878B2 (ja) 2013-03-12 2018-07-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EP3842424B1 (en) 2013-03-15 2024-12-11 The Trustees of Columbia University in the City of New York Map kinase modulators and uses thereof in the tretament of tauopathies
CA2907726A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105764502A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群及其类似物及衍生物的治疗益处的组合方法
WO2015028848A1 (en) * 2013-09-02 2015-03-05 Piramal Enterprises Limited Bicyclic heterocyclic compounds as multi-kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
SI3057953T1 (sl) 2013-10-17 2018-12-31 Vertex Pharmaceuticals Incorporated Ko-kristali(s)-n-metil-8-(1-((2'-metil-(4,5'-bipimiridin)-6-il)amino) propan-2-il)kinolin-4-karboksamida in njegovi devterirani derivati kot inhibitorji dna-pk
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
WO2015103355A1 (en) 2014-01-01 2015-07-09 Medivation Technologies, Inc. Compounds and methods of use
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP4299128A3 (en) 2014-03-13 2024-04-17 Neuroderm Ltd. Dopa decarboxylase inhibitor compositions
JP6517318B2 (ja) * 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
WO2015150097A1 (en) 2014-04-04 2015-10-08 Iomet Pharma Ltd Indole derivatives for use in medicine
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN105367555B (zh) * 2014-08-07 2019-06-25 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
PL3604294T3 (pl) 2014-10-13 2021-11-02 Yuhan Corporation Związki i kompozycje do modulowania aktywności zmutowanych kinaz EGFR
HK1245260A1 (zh) 2014-12-23 2018-08-24 Dana-Farber Cancer Institute, Inc. 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
KR102034202B1 (ko) 2014-12-23 2019-10-18 에스엠에이 세라퓨틱스 아이엔씨. 3,5-디아미노피라졸 키나제 억제제
WO2016123627A1 (en) * 2015-01-30 2016-08-04 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
AU2016247858B2 (en) 2015-04-17 2020-10-15 Ludwig Institute For Cancer Research Ltd. PLK4 inhibitors
SMT201900587T1 (it) 2015-05-28 2019-11-13 Theravance Biopharma R&D Ip Llc Composti di naftiridina come inibitori di chinasi jak
JP2018135268A (ja) * 2015-06-05 2018-08-30 大日本住友製薬株式会社 新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
MX382671B (es) 2015-12-10 2025-03-13 Ptc Therapeutics Inc Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
CN105384702B (zh) * 2015-12-11 2018-04-10 浙江大学 三取代均三嗪类化合物及其制备方法
CN105399695B (zh) * 2015-12-11 2019-04-19 浙江大学 三嗪类化合物及其制备方法和用途
CN105503754B (zh) * 2015-12-11 2017-11-17 浙江大学 2‑氨基‑4‑苄基‑6‑吗啉‑1,3,5‑三嗪及其制备和应用
EP3390387B1 (en) 2015-12-18 2021-11-17 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
RU2761439C2 (ru) 2016-03-14 2021-12-08 Эфферент Фармасьютикалз Инк. Пиримидины, их варианты и применение
EP3433258B1 (en) 2016-03-25 2023-07-19 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
TWI726094B (zh) 2016-04-28 2021-05-01 美商施萬生物製藥研發Ｉｐ有限責任公司 作為jak激酶抑制劑之嘧啶化合物
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
AU2017335648B2 (en) 2016-09-27 2022-02-17 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
US10858319B2 (en) 2016-10-03 2020-12-08 Iomet Pharma Ltd. Indole derivatives for use in medicine
US10968227B2 (en) * 2016-11-08 2021-04-06 Vanderbilt University Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CN108239071B (zh) * 2016-12-27 2020-12-04 沈阳药科大学 酰胺及硫代酰胺类衍生物及其制备方法和应用
FR3064275B1 (fr) 2017-03-21 2019-06-07 Arkema France Procede de chauffage et/ou climatisation d'un vehicule
EA201992764A1 (ru) 2017-05-30 2020-04-29 Басф Се Пиридиновые и пиразиновые соединения
JP7376471B2 (ja) 2017-06-05 2023-11-08 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CA3063616A1 (en) 2017-06-30 2019-12-06 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
CN110573501B (zh) 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP7039802B2 (ja) 2017-06-30 2022-03-23 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、ｒｈｏ－関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
EP3676264A1 (en) * 2017-08-28 2020-07-08 Acurastem Inc. Pikfyve kinase inhibitors
EP3675860B1 (en) * 2017-08-28 2023-03-08 Zhihong, Chen Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
HUE060401T2 (hu) 2017-10-27 2023-02-28 Theravance Biopharma R&D Ip Llc Pirimidin vegyület, mint JAK kináz inhibitor
KR20200090198A (ko) * 2017-11-23 2020-07-28 바이오메드 엑스 게엠베하 트로포미오신 수용체 키나제 A(TrkA) 저해제로서의 피리미딘 유도체
EP3720560A4 (en) * 2017-12-06 2022-01-05 Ludwig Institute for Cancer Research Ltd METHOD OF TREATMENT OF CANCER WITH PLK4 INHIBITORS
CN112135825A (zh) 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
EP3810132A4 (en) * 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
EA202092899A1 (ru) 2018-06-27 2021-05-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Гетероарильные соединения для лечения болезни гентингтона
LT3814357T (lt) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
CN111511738B (zh) * 2018-11-30 2023-01-20 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
CA3124422A1 (en) 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2020219640A1 (en) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Pyrimidine jak inhibitors for the treatment of skin diseases
JP7470713B2 (ja) 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
US12428395B2 (en) 2019-08-01 2025-09-30 Sperogenix Therapeutics Limited Heterocyclic compounds as kinase inhibitor and uses thereof
ES2987744T3 (es) 2019-09-18 2024-11-18 Takeda Pharmaceuticals Co Inhibidores de calicreína plasmática y usos de los mismos
JP7695232B2 (ja) 2019-09-18 2025-06-18 武田薬品工業株式会社 ヘテロアリール血漿カリクレインインヒビター
CN110483493A (zh) * 2019-09-19 2019-11-22 广东工业大学 一种二唑类衍生物及其制备方法和应用
JP7744350B2 (ja) 2020-01-13 2025-09-25 バージ アナリティクス，インコーポレイテッド 置換ピラゾロ－ピリミジンおよびその使用
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
WO2022197789A1 (en) * 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Polycyclic inhibitors of plasma kallikrein
CA3213359A1 (en) * 2021-03-26 2022-09-29 Bettina FRANZ Alk-5 inhibitors and uses thereof
IL308346A (en) 2021-05-11 2024-01-01 Oric Pharmaceuticals Inc Polo like kinase 4 inhibitors
MX2024000230A (es) 2021-06-28 2024-04-01 Blueprint Medicines Corp Inhibidores de cdk2.
KR102692529B1 (ko) * 2021-07-01 2024-08-08 한국원자력의학원 Mastl-pp2a를 표적화하는 암의 예방 또는 치료용 약학적 조성물
CN116354938B (zh) * 2021-12-28 2024-02-20 沈阳药科大学 一类喹唑啉衍生物与其类似物的制备方法及应用
CN114276302B (zh) * 2022-01-11 2023-07-25 山东百启生物医药有限公司 一种制备2,4-二氨基喹唑啉衍生物的方法
CN116813595B (zh) * 2022-03-28 2025-07-18 上海医药工业研究院有限公司 喹唑啉类衍生物、其制备方法、药物组合物及应用
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
CN117736198A (zh) * 2022-09-21 2024-03-22 科辉智药生物科技(深圳)有限公司 大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用
CN115403568B (zh) * 2022-09-21 2023-09-29 中山大学 一种喹唑啉类Aurora A共价抑制剂及其制备方法和应用
US20240317777A1 (en) * 2023-02-23 2024-09-26 Accutar Biotechnology Inc. Novel macrocyclic aminopyrazole compounds as cdk2 inhibitors
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US18436A (en) * 1857-10-20 And saml
US3133081A (en) * 1964-05-12 J-aminoindazole derivatives
US2585906A (en) 1952-02-12 Quaternary salts of pyrimdjines
US3935183A (en) * 1970-01-26 1976-01-27 Imperial Chemical Industries Limited Indazole-azo phenyl compounds
BE754242A (fr) * 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US3998951A (en) * 1974-03-13 1976-12-21 Fmc Corporation Substituted 2-arylquinazolines as fungicides
DE2458965C3 (de) 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
MA18829A1 (fr) 1979-05-18 1980-12-31 Ciba Geigy Ag Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
DOP1981004033A (es) * 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
SE8102194L (sv) * 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
SE8102193L (sv) * 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och dess anvendning
JPS58124773A (ja) 1982-01-20 1983-07-25 Mitsui Toatsu Chem Inc ５−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤
EP0136976A3 (de) 1983-08-23 1985-05-15 Ciba-Geigy Ag Verwendung von Phenylpyrimidinen als Pflanzenregulatoren
DE3725638A1 (de) 1987-08-03 1989-02-16 Bayer Ag Neue aryloxy (bzw. thio)aminopyrimidine
JPH0532662A (ja) 1990-11-09 1993-02-09 Nissan Chem Ind Ltd 置換ピラゾール誘導体および農園芸用殺菌剤
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5597920A (en) 1992-04-30 1997-01-28 Neurogen Corporation Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes
JPH0665237A (ja) 1992-05-07 1994-03-08 Nissan Chem Ind Ltd 置換ピラゾール誘導体および農園芸用殺菌剤
ATE325113T1 (de) 1993-10-01 2006-06-15 Novartis Pharma Gmbh Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
JPH10509708A (ja) 1994-11-10 1998-09-22 コア セラピューティクス，インコーポレイティド プロテイン・キナーゼのインヒビターとして有用な医薬ピラゾール組成物
IL117659A (en) * 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
WO1997009325A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
JPH10130150A (ja) 1996-09-05 1998-05-19 Dainippon Pharmaceut Co Ltd 酢酸アミド誘導体からなる医薬
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
WO1998014450A1 (en) 1996-10-02 1998-04-09 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
AU738341B2 (en) 1996-10-11 2001-09-13 Abbott Gmbh & Co. Kg Asparate ester inhibitors of interleukin-1beta converting enzyme
DE19710435A1 (de) * 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
CA2306692C (en) 1997-10-10 2010-09-21 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
US6267952B1 (en) * 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
JP2000026421A (ja) 1998-01-29 2000-01-25 Kumiai Chem Ind Co Ltd ジアリ―ルスルフィド誘導体及び有害生物防除剤
CA2321153A1 (en) 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
AU755273B2 (en) 1998-03-16 2002-12-05 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
YU76100A (sh) 1998-06-02 2003-12-31 Osi Pharmaceuticals Inc. Pirolo(2,3-d) pirimidin preparati i njihova primena
CN1312807A (zh) 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
WO2000003901A1 (de) * 1998-07-16 2000-01-27 Continental Teves Ag & Co. Ohg Verfahren und vorrichtung zum ermitteln von kritischen fahrzuständen bei im fahrbetrieb befindlichen fahrzeugen
AU5777299A (en) * 1998-08-21 2000-03-14 Du Pont Pharmaceuticals Company Isoxazolo(4,5-d)pyrimidines as CRF antagonists
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
BR9914326A (pt) * 1998-10-08 2001-06-26 Astrazeneca Ab Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou de redução da permeabilidade vascular em animais de sangue quente em necessidade de um tal tratamento
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
WO2000042029A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company 1-heterocycle substituted diarylamines
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
AU766081B2 (en) 1999-03-30 2003-10-09 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
JP2003502424A (ja) 1999-06-17 2003-01-21 シオノギ バイオリサーチ コーポレイション Ｉｌ−１２産生の阻害物質
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
CA2381882C (en) 1999-08-13 2011-01-25 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
EA200200411A1 (ru) 1999-11-30 2002-10-31 Пфайзер Продактс Инк. 2,4-диаминопиримидиновые соединения, полезные в качестве иммуносупрессоров
AU784878B2 (en) 1999-12-02 2006-07-13 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 A2A and A3 receptors and uses thereof
MY125768A (en) 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6376489B1 (en) 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
JP2003519143A (ja) 1999-12-28 2003-06-17 ファーマコピーア，インコーポレーティッド ピリミジン及びトリアジン系キナーゼ阻害剤
KR20010111298A (ko) * 2000-02-05 2001-12-17 버텍스 파마슈티칼스 인코포레이티드 Ｅｒｋ의 억제제로서 유용한 피라졸 조성물
JP2003532635A (ja) * 2000-02-17 2003-11-05 アムジエン・インコーポレーテツド キナーゼ阻害薬
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
JP4806154B2 (ja) 2000-04-03 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
CA2398446A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
JP3890184B2 (ja) * 2000-05-15 2007-03-07 Ｎｅｃパーソナルプロダクツ株式会社 電源装置及びその電力制御方法、情報処理機器
WO2002000649A1 (en) * 2000-06-28 2002-01-03 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
ES2341534T3 (es) 2000-07-21 2010-06-22 Schering Corporation Peptidos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
EP1313710A1 (en) 2000-08-31 2003-05-28 Pfizer Products Inc. Pyrazole derivatives and their use as protein kinase inhibitors
ATE346064T1 (de) * 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1317453B1 (en) * 2000-09-15 2006-08-09 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1318984A1 (en) 2000-09-20 2003-06-18 MERCK PATENT GmbH 4-amino-quinazolines
US6641579B1 (en) * 2000-09-29 2003-11-04 Spectrasonics Imaging, Inc. Apparatus and method for ablating cardiac tissue
DE10061863A1 (de) * 2000-12-12 2002-06-13 Basf Ag Verfahren zur Herstellung von Triethylendiamin (TEDA)
AU2002228922A1 (en) 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
WO2002068415A1 (en) * 2000-12-21 2002-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US6949544B2 (en) * 2001-03-29 2005-09-27 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
DE60214701T2 (de) * 2001-04-13 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
WO2002085909A1 (en) * 2001-04-20 2002-10-31 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
EP1404669A2 (en) * 2001-05-16 2004-04-07 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
ATE432929T1 (de) * 2001-06-15 2009-06-15 Vertex Pharma 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
ATE337312T1 (de) * 2001-07-03 2006-09-15 Vertex Pharma Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
WO2003026664A1 (en) * 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
US6569499B2 (en) * 2001-10-02 2003-05-27 Xerox Corporation Apparatus and method for coating photoreceptor substrates
EP2198867A1 (en) * 2001-12-07 2010-06-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
US7091343B2 (en) * 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2003225800A1 (en) * 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
ATE365733T1 (de) * 2002-03-15 2007-07-15 Vertex Pharma Zusammensetzungen brauchbar als protein-kinase- inhibitoren
US20040009981A1 (en) * 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
US20030207873A1 (en) * 2002-04-10 2003-11-06 Edmund Harrington Inhibitors of Src and other protein kinases
WO2003091246A1 (en) * 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
JP4570955B2 (ja) * 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド プロテインキナーゼ阻害活性を持つイミダゾール類
JP4733388B2 (ja) 2002-08-02 2011-07-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ｇｓｋ−３のインヒビターとして有用なピラゾール組成物
ES2535854T3 (es) 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
AU2007333650A1 (en) 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases

Cited By (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20070270444A1 (en) * 2000-09-15 2007-11-22 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US8524720B2 (en) 2000-09-15 2013-09-03 Vertex Pharmaceuticals Incorporated Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors
US8633210B2 (en) 2000-09-15 2014-01-21 Vertex Pharmaceuticals Incorporated Triazole compounds useful as protein kinase inhibitors
US7390815B2 (en) 2000-09-15 2008-06-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20040116454A1 (en) * 2000-09-15 2004-06-17 Robert Davies Pyrazole compounds useful as protein kinase inhibitors
US20030064982A1 (en) * 2000-09-15 2003-04-03 Robert Davies Pyrazole compounds useful as protein kinase inhibitors
US20100256170A1 (en) * 2000-09-15 2010-10-07 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7951820B2 (en) 2000-09-15 2011-05-31 Vertex Pharmaceuticals Incorporated Triazole compounds useful as protein kinase inhibitors
US7691853B2 (en) 2000-09-15 2010-04-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20060258658A1 (en) * 2000-09-15 2006-11-16 David Bebbington Triazole compounds useful as protein kinase inhibitors
US20040167141A1 (en) * 2000-12-21 2004-08-26 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US8697698B2 (en) 2000-12-21 2014-04-15 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7531536B2 (en) 2000-12-21 2009-05-12 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20040214814A1 (en) * 2000-12-21 2004-10-28 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US20080287444A1 (en) * 2000-12-21 2008-11-20 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US8304414B2 (en) 2000-12-21 2012-11-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7427681B2 (en) 2000-12-21 2008-09-23 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20040157893A1 (en) * 2000-12-21 2004-08-12 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US20050038023A1 (en) * 2000-12-21 2005-02-17 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US7625913B2 (en) 2000-12-21 2009-12-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20090131463A1 (en) * 2001-12-07 2009-05-21 Astrazeneca Ab Novel compounds
US20070270420A1 (en) * 2002-02-06 2007-11-22 Harbeson Scott L Heteroaryl compounds useful as inhibitors of gsk-3
US20070190634A1 (en) * 2002-03-15 2007-08-16 David Bebbington Compositions useful as inhibitors of protein kinases
US8669081B2 (en) 2002-03-15 2014-03-11 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7557106B2 (en) 2002-06-20 2009-07-07 Vertex Pharmaceuticals Incorporated Substituted pyrimidines useful as protein kinase inhibitors
US8268829B2 (en) 2002-06-20 2012-09-18 Vertex Pharmaceuticals Inc. Substituted pyrimidines useful as protein kinase inhibitors
US20090221602A1 (en) * 2002-06-20 2009-09-03 Vertex Pharmaceuticals Incorporated Processes for preparing substituted pyrimidines
US8779127B2 (en) 2002-06-20 2014-07-15 Vertex Pharmaceuticals Incorporated Processes for preparing substituted pyrimidines
US20060270660A1 (en) * 2002-06-20 2006-11-30 Vertex Pharmaceuticals Incorporated Processes for preparing substituted pyrimidines
US7491730B2 (en) 2002-08-02 2009-02-17 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of GSK-3
US8653088B2 (en) 2003-02-06 2014-02-18 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20090325968A1 (en) * 2003-02-06 2009-12-31 Vertex Pharmaceuticals Incorporated Compositions Useful as Inhibitors of Protein Kinases
US20080039479A1 (en) * 2003-07-03 2008-02-14 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
US20070249601A1 (en) * 2003-07-03 2007-10-25 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
US7989462B2 (en) 2003-07-03 2011-08-02 Myrexis, Inc. 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20070208044A1 (en) * 2003-07-03 2007-09-06 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
US20070244113A1 (en) * 2003-07-03 2007-10-18 Myriad Genetics, Incorporated Compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US7618975B2 (en) 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20100081657A1 (en) * 2003-12-04 2010-04-01 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
US20050153966A1 (en) * 2003-12-19 2005-07-14 Syrrx, Inc. Kinase inhibitors
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20060041137A1 (en) * 2004-08-18 2006-02-23 Takeda San Diego, Inc. Kinase inhibitors
US20060084650A1 (en) * 2004-10-15 2006-04-20 Qing Dong Kinase inhibitors
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8288536B2 (en) 2004-10-15 2012-10-16 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8153630B2 (en) 2004-11-17 2012-04-10 Miikana Therapeutics, Inc. Kinase inhibitors
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US20080176872A1 (en) * 2005-02-16 2008-07-24 Astrazeneca Ab Chemical Compounds
US8129403B2 (en) 2005-02-16 2012-03-06 Astrazeneca Ab Chemical compounds
US8114989B2 (en) 2005-05-16 2012-02-14 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
US20100210648A1 (en) * 2005-05-16 2010-08-19 Astrazeneca R&D Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
US20100222367A1 (en) * 2005-08-18 2010-09-02 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
US7737151B2 (en) 2005-08-18 2010-06-15 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
US20070173516A1 (en) * 2005-08-18 2007-07-26 Michael Mortimore Pyrazine kinase inhibitors
US7989456B2 (en) * 2005-08-18 2011-08-02 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
US8114870B2 (en) 2005-09-30 2012-02-14 Miikana Therapeutics, Inc. Method of treating disease states using substituted pyrazole compounds
US20070142368A1 (en) * 2005-09-30 2007-06-21 Xiao-Yi Xiao Substituted pyrazole compounds
US20090264422A1 (en) * 2005-09-30 2009-10-22 Xiao-Yi Xiao Method of treating disease states using substituted pyrazole compounds
US7563787B2 (en) 2005-09-30 2009-07-21 Miikana Therapeutics, Inc. Substituted pyrazole compounds
US20070117816A1 (en) * 2005-10-07 2007-05-24 Brown Jason W Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20100160325A1 (en) * 2005-10-28 2010-06-24 Astrazeneca Ab 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US8088784B2 (en) 2005-10-28 2012-01-03 Astrazeneca Ab 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US7820685B2 (en) 2005-11-03 2010-10-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8557833B2 (en) 2005-11-03 2013-10-15 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US20110020469A1 (en) * 2005-11-03 2011-01-27 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US20070249031A1 (en) * 2005-11-03 2007-10-25 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8637511B2 (en) 2005-11-03 2014-01-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US7767672B2 (en) 2005-11-03 2010-08-03 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US20070259869A1 (en) * 2005-11-03 2007-11-08 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US20080032963A1 (en) * 2005-11-03 2008-02-07 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US7528142B2 (en) 2005-11-03 2009-05-05 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8129399B2 (en) 2005-11-03 2012-03-06 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US20090181938A1 (en) * 2005-11-03 2009-07-16 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US20100310675A1 (en) * 2005-11-03 2010-12-09 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8088821B2 (en) 2006-06-27 2012-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
US8598226B2 (en) 2006-06-27 2013-12-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
US8492430B2 (en) 2006-06-27 2013-07-23 Takeda Pharmaceutical Company Limited Fused cyclic compounds
US20100197761A1 (en) * 2006-06-27 2010-08-05 Tsuneo Yasuma Fused cyclic compounds
US20080004302A1 (en) * 2006-06-30 2008-01-03 Astrazeneca Ab Novel Compounds
US20100022502A1 (en) * 2006-11-02 2010-01-28 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
US8372850B2 (en) 2006-11-02 2013-02-12 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
US20100022507A1 (en) * 2006-12-19 2010-01-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US8426425B2 (en) 2006-12-19 2013-04-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US8410133B2 (en) 2007-03-09 2013-04-02 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
US20110020376A1 (en) * 2007-03-09 2011-01-27 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US20110020377A1 (en) * 2007-03-09 2011-01-27 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US8518953B2 (en) 2007-03-09 2013-08-27 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US20110021559A1 (en) * 2007-03-09 2011-01-27 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
US8664219B2 (en) 2007-03-09 2014-03-04 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
US8735593B2 (en) 2007-03-09 2014-05-27 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
US8455507B2 (en) 2007-04-13 2013-06-04 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US20090156557A1 (en) * 2007-04-18 2009-06-18 Takeda San Diego, Inc. Kinase inhibitors
US8278450B2 (en) 2007-04-18 2012-10-02 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20100204246A1 (en) * 2007-04-18 2010-08-12 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo (4,5-b) pyridine derivatives and their use for the treatment of cancer
US8785444B2 (en) 2007-05-02 2014-07-22 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
US8268811B2 (en) 2007-05-02 2012-09-18 Vertex Pharmaceuticals Inc. Thiazoles and pyrazoles useful as kinase inhibitors
US20100215772A1 (en) * 2007-05-02 2010-08-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8383633B2 (en) 2007-05-02 2013-02-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US20100317641A1 (en) * 2007-05-02 2010-12-16 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
US20110046104A1 (en) * 2007-05-02 2011-02-24 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US8486966B2 (en) 2007-05-04 2013-07-16 Astrazeneca Ab 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer
US20100324040A1 (en) * 2007-05-04 2010-12-23 Astrazeneca Ab 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyrazol-3-yl) -3h-imidazo[4,5-b] pyridin-5- amine derivatives and their use for the treatment of cancer
US20110060013A1 (en) * 2007-05-24 2011-03-10 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
US20090029992A1 (en) * 2007-06-11 2009-01-29 Agoston Gregory E Substituted pyrazole compounds
US20100184980A1 (en) * 2007-07-31 2010-07-22 Juan-Miguel Jimenez Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof
US8598361B2 (en) 2007-07-31 2013-12-03 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives therof
US8242272B2 (en) 2007-07-31 2012-08-14 Vertex Pharmaceuticals Inc. Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives thereof
US20110183954A1 (en) * 2008-06-11 2011-07-28 Astrazeneca Ab Tricyclic 2,4-diamino-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
US8541025B2 (en) 2008-09-03 2013-09-24 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
US20110236478A1 (en) * 2008-09-03 2011-09-29 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
US20110201628A1 (en) * 2008-09-30 2011-08-18 Astrazeneca Ab Heterocyclic jak kinase inhibitors
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
US8354420B2 (en) 2010-06-04 2013-01-15 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 inhibitors
US8633207B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
US8815882B2 (en) 2010-11-10 2014-08-26 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
US9006241B2 (en) 2011-03-24 2015-04-14 Noviga Research Ab Pyrimidine derivatives
US8637537B2 (en) 2011-08-25 2014-01-28 Genentech, Inc. Serine/threonine kinase inhibitors
US8815877B2 (en) 2011-12-22 2014-08-26 Genentech, Inc. Serine/threonine kinase inhibitors

Also Published As

Publication number Publication date
JP2008201808A (ja) 2008-09-04
IL156389A (en) 2011-01-31
CA2432799A1 (en) 2002-06-27
AU2006201267A1 (en) 2006-04-27
CA2432222A1 (en) 2002-08-15
JP2004519479A (ja) 2004-07-02
EP1345927A1 (en) 2003-09-24
US6664247B2 (en) 2003-12-16
AU2002246754B2 (en) 2006-06-08
CA2432129A1 (en) 2002-07-25
CA2432872A1 (en) 2002-06-27
JP2008247921A (ja) 2008-10-16
CN1486312A (zh) 2004-03-31
CA2432222C (en) 2008-07-29
CN102250071A (zh) 2011-11-23
AP2003002825A0 (en) 2003-09-30
EP1702920B1 (en) 2011-10-12
WO2002059111A2 (en) 2002-08-01
US6989385B2 (en) 2006-01-24
NO20032671D0 (no) 2003-06-12
CA2432303C (en) 2010-04-13
JP2004517926A (ja) 2004-06-17
US7982037B2 (en) 2011-07-19
NZ526474A (en) 2005-10-28
AR042398A1 (es) 2005-06-22
CN100406454C (zh) 2008-07-30
MXPA03005612A (es) 2003-10-06
ES2375491T3 (es) 2012-03-01
WO2002057259A2 (en) 2002-07-25
ATE354573T1 (de) 2007-03-15
DE60119774D1 (de) 2006-06-22
WO2002068415A1 (en) 2002-09-06
ATE340172T1 (de) 2006-10-15
PT1345922E (pt) 2006-09-29
ES2272567T3 (es) 2007-05-01
AU2006201267B2 (en) 2010-07-29
AU3116602A (en) 2002-07-01
MXPA03005606A (es) 2003-10-06
KR20030061463A (ko) 2003-07-18
DE60119774T2 (de) 2007-05-16
DK1353916T3 (da) 2007-01-29
WO2002050066A2 (en) 2002-06-27
CA2432223A1 (en) 2002-09-06
US20030055068A1 (en) 2003-03-20
HK1061389A1 (en) 2004-09-17
NO20032670D0 (no) 2003-06-12
US6656939B2 (en) 2003-12-02
MXPA03005607A (es) 2003-10-06
WO2002066461A1 (en) 2002-08-29
WO2002059112A3 (en) 2003-02-06
AU2002231166B2 (en) 2008-02-21
CN1486310A (zh) 2004-03-31
KR100889246B1 (ko) 2009-03-19
IL156407A0 (en) 2004-01-04
AU2001297619B2 (en) 2006-06-08
JP2004516291A (ja) 2004-06-03
JP4160395B2 (ja) 2008-10-01
KR20030061857A (ko) 2003-07-22
HUP0400908A3 (en) 2010-03-29
JP2008222719A (ja) 2008-09-25
EP1345926B1 (en) 2006-05-17
ES2265446T3 (es) 2007-02-16
WO2002050065A3 (en) 2002-10-24
DE60119777T2 (de) 2007-05-03
HUP0400638A2 (hu) 2004-06-28
ES2265450T3 (es) 2007-02-16
HUP0400639A2 (hu) 2004-06-28
NZ526468A (en) 2004-03-26
IL156408A0 (en) 2004-01-04
KR20030061467A (ko) 2003-07-18
US20040132781A1 (en) 2004-07-08
EP1345926A2 (en) 2003-09-24
HUP0400641A2 (hu) 2004-06-28
HK1060346A1 (en) 2004-08-06
EP1355905A1 (en) 2003-10-29
HK1060349A1 (en) 2004-08-06
ATE327989T1 (de) 2006-06-15
CA2432223C (en) 2008-05-20
ATE326460T1 (de) 2006-06-15
US7427681B2 (en) 2008-09-23
US20090312543A1 (en) 2009-12-17
WO2002057259A3 (en) 2003-04-24
NO20032703L (no) 2003-08-19
PT1353916E (pt) 2007-01-31
KR20030061465A (ko) 2003-07-18
EP1345928B1 (en) 2007-02-14
US6653300B2 (en) 2003-11-25
JP2008247920A (ja) 2008-10-16
NO20032703D0 (no) 2003-06-13
AP2003002816A0 (en) 2003-06-30
NO20032670L (no) 2003-08-15
EP1345922B1 (en) 2006-05-31
DE60123283D1 (de) 2006-11-02
ATE528303T1 (de) 2011-10-15
KR100843114B1 (ko) 2008-07-02
EP1345929A2 (en) 2003-09-24
DE60123283T2 (de) 2007-04-12
HK1060347A1 (en) 2004-08-06
NZ526469A (en) 2005-10-28
US7531536B2 (en) 2009-05-12
CN1487933A (zh) 2004-04-07
US20030022885A1 (en) 2003-01-30
CA2432872C (en) 2008-09-23
NZ526473A (en) 2005-06-24
CN100408573C (zh) 2008-08-06
EP1345925A2 (en) 2003-09-24
RU2003122209A (ru) 2005-02-10
JP4234435B2 (ja) 2009-03-04
SI1355905T1 (sl) 2007-08-31
CA2432132C (en) 2008-07-29
HUP0400908A2 (hu) 2004-07-28
US20140187772A1 (en) 2014-07-03
KR20030061464A (ko) 2003-07-18
JP2004517927A (ja) 2004-06-17
PL363246A1 (en) 2004-11-15
TW200716617A (en) 2007-05-01
HK1059776A1 (en) 2004-07-16
DE60120219D1 (de) 2006-07-06
MXPA03005608A (es) 2003-10-06
TWI290551B (en) 2007-12-01
US20130096128A1 (en) 2013-04-18
PT1355905E (pt) 2007-05-31
KR100909665B1 (ko) 2009-07-29
US20040157893A1 (en) 2004-08-12
DE60126828T2 (de) 2007-11-08
BR0116493A (pt) 2003-09-30
KR20030061468A (ko) 2003-07-18
DE60119777D1 (de) 2006-06-22
CN1486311A (zh) 2004-03-31
CA2432131C (en) 2008-07-08
ATE326462T1 (de) 2006-06-15
HK1062565A1 (zh) 2004-11-12
JP5249842B2 (ja) 2013-07-31
NO20032704D0 (no) 2003-06-13
CN100340555C (zh) 2007-10-03
DK1345922T3 (da) 2006-09-18
HK1062433A1 (en) 2004-11-05
HUP0400842A2 (hu) 2004-07-28
CA2432131A1 (en) 2002-08-01
CA2432303A1 (en) 2002-08-29
US20030004161A1 (en) 2003-01-02
MXPA03005609A (es) 2003-10-06
PL363244A1 (en) 2004-11-15
PL210414B1 (pl) 2012-01-31
CA2432129C (en) 2008-08-26
EP1345925B1 (en) 2006-05-17
DE60126828D1 (de) 2007-04-05
DE60119776D1 (de) 2006-06-22
KR20030061466A (ko) 2003-07-18
MY140377A (en) 2009-12-31
CN100436452C (zh) 2008-11-26
US7625913B2 (en) 2009-12-01
JP2008189682A (ja) 2008-08-21
US20040167141A1 (en) 2004-08-26
MXPA03005611A (es) 2003-10-06
EP1345922A1 (en) 2003-09-24
JP4210520B2 (ja) 2009-01-21
AR040925A1 (es) 2005-04-27
EP2264028A1 (en) 2010-12-22
DE60126658T2 (de) 2007-11-22
DE60119775D1 (de) 2006-06-22
AU2002234047A1 (en) 2002-07-01
JP2004518703A (ja) 2004-06-24
ATE326461T1 (de) 2006-06-15
NO20032736L (no) 2003-08-18
SI1353916T1 (sl) 2007-02-28
US8304414B2 (en) 2012-11-06
CY1106297T1 (el) 2011-10-12
JP2008189687A (ja) 2008-08-21
EP1353916A2 (en) 2003-10-22
AU2002255452B2 (en) 2006-06-08
US6653301B2 (en) 2003-11-25
DE60119775T2 (de) 2007-05-10
JP2009155352A (ja) 2009-07-16
HK1060557A1 (en) 2004-08-13
IL156369A (en) 2011-02-28
JP2004518743A (ja) 2004-06-24
JP2005097322A (ja) 2005-04-14
IL156368A0 (en) 2004-01-04
US20080287444A1 (en) 2008-11-20
PL210066B1 (pl) 2011-11-30
AR042397A1 (es) 2005-06-22
WO2002050065A2 (en) 2002-06-27
EP1345928A2 (en) 2003-09-24
DE60119776T2 (de) 2007-05-16
NZ526471A (en) 2005-08-26
BR0116411A (pt) 2003-11-11
MXPA03005610A (es) 2003-10-06
ATE353890T1 (de) 2007-03-15
NZ526470A (en) 2006-03-31
JP2004517894A (ja) 2004-06-17
WO2002059112A2 (en) 2002-08-01
US20040214814A1 (en) 2004-10-28
AR042169A1 (es) 2005-06-15
WO2002050066A3 (en) 2003-01-23
IL209827A0 (en) 2011-02-28
KR100947185B1 (ko) 2010-03-15
JP2013213068A (ja) 2013-10-17
JP2008260767A (ja) 2008-10-30
CA2432132A1 (en) 2002-08-01
HUP0400639A3 (en) 2010-03-29
IL156389A0 (en) 2004-01-04
TWI313269B (en) 2009-08-11
HUP0400641A3 (en) 2010-03-29
NZ526472A (en) 2004-04-30
NO20032671L (no) 2003-08-18
US8697698B2 (en) 2014-04-15
CA2432799C (en) 2008-08-19
JP2004516292A (ja) 2004-06-03
IL156369A0 (en) 2004-01-04
NO20032704L (no) 2003-08-21
EP1702920A1 (en) 2006-09-20
EP1353916B1 (en) 2006-09-20
RU2355688C2 (ru) 2009-05-20
US7087603B2 (en) 2006-08-08
US20050038023A1 (en) 2005-02-17
AP1588A (en) 2006-03-06
EP1345927B1 (en) 2006-05-17
EP1345929B1 (en) 2006-05-17
JP2009286805A (ja) 2009-12-10
US20030036543A1 (en) 2003-02-20
DE60120219T2 (de) 2007-04-12
JP4160392B2 (ja) 2008-10-01
CN1549812A (zh) 2004-11-24
WO2002059111A3 (en) 2003-01-09
ES2280313T3 (es) 2007-09-16
US20030004164A1 (en) 2003-01-02
ES2265452T3 (es) 2007-02-16
JP4160389B2 (ja) 2008-10-01
NO330527B1 (no) 2011-05-09
KR20030061858A (ko) 2003-07-22
US6727251B2 (en) 2004-04-27
NO328537B1 (no) 2010-03-15
DK1355905T3 (da) 2007-06-18
DE60126658D1 (de) 2007-03-29
KR100875091B1 (ko) 2008-12-22
WO2002062789A1 (en) 2002-08-15
US20030078275A1 (en) 2003-04-24
NZ526475A (en) 2005-06-24
ES2266095T3 (es) 2007-03-01
NO328501B1 (no) 2010-03-01
MXPA03005605A (es) 2003-10-06
NO20032736D0 (no) 2003-06-16
ATE326463T1 (de) 2006-06-15
EP1355905B1 (en) 2007-02-21

Similar Documents

Publication Publication Date Title
US6664247B2 (en) Pyrazole compounds useful as protein kinase inhibitors
AU2001297619A1 (en) Pyrazole compounds useful as protein kinase inhibitors
AU2002255452A1 (en) Pyrazole compounds useful as protein kinase inhibitors
RU2332415C2 (ru) Производные пиразола, полезные в качестве ингибиторов протеинкиназы
AU2002246731A1 (en) Pyrazole compounds useful as protein kinase inhibitors
AU2002246899A1 (en) Pyrazole compounds useful as protein kinase inhibitors
AU2002245198A1 (en) Pyrazole compounds useful as protein kinase inhibitors
HK1059776B (en) Pyrazole compounds useful as protein kinase inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: VERTEX PHARMACEUTICALS INCORPORATED, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BEBBINGTON, DAVID;CHARRIER, JEAN-DAMIEN;REEL/FRAME:013901/0344;SIGNING DATES FROM 20030808 TO 20030813

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION